<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Claude Code transcript - page 4</title>
    <style>
:root { --bg-color: #f5f5f5; --card-bg: #ffffff; --user-bg: #e3f2fd; --user-border: #1976d2; --assistant-bg: #f5f5f5; --assistant-border: #9e9e9e; --thinking-bg: #fff8e1; --thinking-border: #ffc107; --thinking-text: #666; --tool-bg: #f3e5f5; --tool-border: #9c27b0; --tool-result-bg: #e8f5e9; --tool-error-bg: #ffebee; --text-color: #212121; --text-muted: #757575; --code-bg: #263238; --code-text: #aed581; }
* { box-sizing: border-box; }
body { font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif; background: var(--bg-color); color: var(--text-color); margin: 0; padding: 16px; line-height: 1.6; }
.container { max-width: 800px; margin: 0 auto; }
h1 { font-size: 1.5rem; margin-bottom: 24px; padding-bottom: 8px; border-bottom: 2px solid var(--user-border); }
.header-row { display: flex; justify-content: space-between; align-items: center; flex-wrap: wrap; gap: 12px; border-bottom: 2px solid var(--user-border); padding-bottom: 8px; margin-bottom: 24px; }
.header-row h1 { border-bottom: none; padding-bottom: 0; margin-bottom: 0; flex: 1; min-width: 200px; }
.message { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.message.user { background: var(--user-bg); border-left: 4px solid var(--user-border); }
.message.assistant { background: var(--card-bg); border-left: 4px solid var(--assistant-border); }
.message.tool-reply { background: #fff8e1; border-left: 4px solid #ff9800; }
.tool-reply .role-label { color: #e65100; }
.tool-reply .tool-result { background: transparent; padding: 0; margin: 0; }
.tool-reply .tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.message-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.role-label { font-weight: 600; text-transform: uppercase; letter-spacing: 0.5px; }
.user .role-label { color: var(--user-border); }
time { color: var(--text-muted); font-size: 0.8rem; }
.timestamp-link { color: inherit; text-decoration: none; }
.timestamp-link:hover { text-decoration: underline; }
.message:target { animation: highlight 2s ease-out; }
@keyframes highlight { 0% { background-color: rgba(25, 118, 210, 0.2); } 100% { background-color: transparent; } }
.message-content { padding: 16px; }
.message-content p { margin: 0 0 12px 0; }
.message-content p:last-child { margin-bottom: 0; }
.thinking { background: var(--thinking-bg); border: 1px solid var(--thinking-border); border-radius: 8px; padding: 12px; margin: 12px 0; font-size: 0.9rem; color: var(--thinking-text); }
.thinking-label { font-size: 0.75rem; font-weight: 600; text-transform: uppercase; color: #f57c00; margin-bottom: 8px; }
.thinking p { margin: 8px 0; }
.assistant-text { margin: 8px 0; }
.tool-use { background: var(--tool-bg); border: 1px solid var(--tool-border); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-header { font-weight: 600; color: var(--tool-border); margin-bottom: 8px; display: flex; align-items: center; gap: 8px; }
.tool-icon { font-size: 1.1rem; }
.tool-description { font-size: 0.9rem; color: var(--text-muted); margin-bottom: 8px; font-style: italic; }
.tool-result { background: var(--tool-result-bg); border-radius: 8px; padding: 12px; margin: 12px 0; }
.tool-result.tool-error { background: var(--tool-error-bg); }
.file-tool { border-radius: 8px; padding: 12px; margin: 12px 0; }
.write-tool { background: linear-gradient(135deg, #e3f2fd 0%, #e8f5e9 100%); border: 1px solid #4caf50; }
.edit-tool { background: linear-gradient(135deg, #fff3e0 0%, #fce4ec 100%); border: 1px solid #ff9800; }
.file-tool-header { font-weight: 600; margin-bottom: 4px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.write-header { color: #2e7d32; }
.edit-header { color: #e65100; }
.file-tool-icon { font-size: 1rem; }
.file-tool-path { font-family: monospace; background: rgba(0,0,0,0.08); padding: 2px 8px; border-radius: 4px; }
.file-tool-fullpath { font-family: monospace; font-size: 0.8rem; color: var(--text-muted); margin-bottom: 8px; word-break: break-all; }
.file-content { margin: 0; }
.edit-section { display: flex; margin: 4px 0; border-radius: 4px; overflow: hidden; }
.edit-label { padding: 8px 12px; font-weight: bold; font-family: monospace; display: flex; align-items: flex-start; }
.edit-old { background: #fce4ec; }
.edit-old .edit-label { color: #b71c1c; background: #f8bbd9; }
.edit-old .edit-content { color: #880e4f; }
.edit-new { background: #e8f5e9; }
.edit-new .edit-label { color: #1b5e20; background: #a5d6a7; }
.edit-new .edit-content { color: #1b5e20; }
.edit-content { margin: 0; flex: 1; background: transparent; font-size: 0.85rem; }
.edit-replace-all { font-size: 0.75rem; font-weight: normal; color: var(--text-muted); }
.write-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #e6f4ea); }
.edit-tool .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff0e5); }
.todo-list { background: linear-gradient(135deg, #e8f5e9 0%, #f1f8e9 100%); border: 1px solid #81c784; border-radius: 8px; padding: 12px; margin: 12px 0; }
.todo-header { font-weight: 600; color: #2e7d32; margin-bottom: 10px; display: flex; align-items: center; gap: 8px; font-size: 0.95rem; }
.todo-items { list-style: none; margin: 0; padding: 0; }
.todo-item { display: flex; align-items: flex-start; gap: 10px; padding: 6px 0; border-bottom: 1px solid rgba(0,0,0,0.06); font-size: 0.9rem; }
.todo-item:last-child { border-bottom: none; }
.todo-icon { flex-shrink: 0; width: 20px; height: 20px; display: flex; align-items: center; justify-content: center; font-weight: bold; border-radius: 50%; }
.todo-completed .todo-icon { color: #2e7d32; background: rgba(46, 125, 50, 0.15); }
.todo-completed .todo-content { color: #558b2f; text-decoration: line-through; }
.todo-in-progress .todo-icon { color: #f57c00; background: rgba(245, 124, 0, 0.15); }
.todo-in-progress .todo-content { color: #e65100; font-weight: 500; }
.todo-pending .todo-icon { color: #757575; background: rgba(0,0,0,0.05); }
.todo-pending .todo-content { color: #616161; }
pre { background: var(--code-bg); color: var(--code-text); padding: 12px; border-radius: 6px; overflow-x: auto; font-size: 0.85rem; line-height: 1.5; margin: 8px 0; white-space: pre-wrap; word-wrap: break-word; }
pre.json { color: #e0e0e0; }
code { background: rgba(0,0,0,0.08); padding: 2px 6px; border-radius: 4px; font-size: 0.9em; }
pre code { background: none; padding: 0; }
.user-content { margin: 0; }
.truncatable { position: relative; }
.truncatable.truncated .truncatable-content { max-height: 200px; overflow: hidden; }
.truncatable.truncated::after { content: ''; position: absolute; bottom: 32px; left: 0; right: 0; height: 60px; background: linear-gradient(to bottom, transparent, var(--card-bg)); pointer-events: none; }
.message.user .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--user-bg)); }
.message.tool-reply .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, #fff8e1); }
.tool-use .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-bg)); }
.tool-result .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--tool-result-bg)); }
.expand-btn { display: none; width: 100%; padding: 8px 16px; margin-top: 4px; background: rgba(0,0,0,0.05); border: 1px solid rgba(0,0,0,0.1); border-radius: 6px; cursor: pointer; font-size: 0.85rem; color: var(--text-muted); }
.expand-btn:hover { background: rgba(0,0,0,0.1); }
.truncatable.truncated .expand-btn, .truncatable.expanded .expand-btn { display: block; }
.pagination { display: flex; justify-content: center; gap: 8px; margin: 24px 0; flex-wrap: wrap; }
.pagination a, .pagination span { padding: 5px 10px; border-radius: 6px; text-decoration: none; font-size: 0.85rem; }
.pagination a { background: var(--card-bg); color: var(--user-border); border: 1px solid var(--user-border); }
.pagination a:hover { background: var(--user-bg); }
.pagination .current { background: var(--user-border); color: white; }
.pagination .disabled { color: var(--text-muted); border: 1px solid #ddd; }
.pagination .index-link { background: var(--user-border); color: white; }
details.continuation { margin-bottom: 16px; }
details.continuation summary { cursor: pointer; padding: 12px 16px; background: var(--user-bg); border-left: 4px solid var(--user-border); border-radius: 12px; font-weight: 500; color: var(--text-muted); }
details.continuation summary:hover { background: rgba(25, 118, 210, 0.15); }
details.continuation[open] summary { border-radius: 12px 12px 0 0; margin-bottom: 0; }
.index-item { margin-bottom: 16px; border-radius: 12px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); background: var(--user-bg); border-left: 4px solid var(--user-border); }
.index-item a { display: block; text-decoration: none; color: inherit; }
.index-item a:hover { background: rgba(25, 118, 210, 0.1); }
.index-item-header { display: flex; justify-content: space-between; align-items: center; padding: 8px 16px; background: rgba(0,0,0,0.03); font-size: 0.85rem; }
.index-item-number { font-weight: 600; color: var(--user-border); }
.index-item-content { padding: 16px; }
.index-item-stats { padding: 8px 16px 12px 32px; font-size: 0.85rem; color: var(--text-muted); border-top: 1px solid rgba(0,0,0,0.06); }
.index-item-commit { margin-top: 6px; padding: 4px 8px; background: #fff3e0; border-radius: 4px; font-size: 0.85rem; color: #e65100; }
.index-item-commit code { background: rgba(0,0,0,0.08); padding: 1px 4px; border-radius: 3px; font-size: 0.8rem; margin-right: 6px; }
.commit-card { margin: 8px 0; padding: 10px 14px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 6px; }
.commit-card a { text-decoration: none; color: #5d4037; display: block; }
.commit-card a:hover { color: #e65100; }
.commit-card-hash { font-family: monospace; color: #e65100; font-weight: 600; margin-right: 8px; }
.index-commit { margin-bottom: 12px; padding: 10px 16px; background: #fff3e0; border-left: 4px solid #ff9800; border-radius: 8px; box-shadow: 0 1px 2px rgba(0,0,0,0.05); }
.index-commit a { display: block; text-decoration: none; color: inherit; }
.index-commit a:hover { background: rgba(255, 152, 0, 0.1); margin: -10px -16px; padding: 10px 16px; border-radius: 8px; }
.index-commit-header { display: flex; justify-content: space-between; align-items: center; font-size: 0.85rem; margin-bottom: 4px; }
.index-commit-hash { font-family: monospace; color: #e65100; font-weight: 600; }
.index-commit-msg { color: #5d4037; }
.index-item-long-text { margin-top: 8px; padding: 12px; background: var(--card-bg); border-radius: 8px; border-left: 3px solid var(--assistant-border); }
.index-item-long-text .truncatable.truncated::after { background: linear-gradient(to bottom, transparent, var(--card-bg)); }
.index-item-long-text-content { color: var(--text-color); }
#search-box { display: none; align-items: center; gap: 8px; }
#search-box input { padding: 6px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; width: 180px; }
#search-box button, #modal-search-btn, #modal-close-btn { background: var(--user-border); color: white; border: none; border-radius: 6px; padding: 6px 10px; cursor: pointer; display: flex; align-items: center; justify-content: center; }
#search-box button:hover, #modal-search-btn:hover { background: #1565c0; }
#modal-close-btn { background: var(--text-muted); margin-left: 8px; }
#modal-close-btn:hover { background: #616161; }
#search-modal[open] { border: none; border-radius: 12px; box-shadow: 0 4px 24px rgba(0,0,0,0.2); padding: 0; width: 90vw; max-width: 900px; height: 80vh; max-height: 80vh; display: flex; flex-direction: column; }
#search-modal::backdrop { background: rgba(0,0,0,0.5); }
.search-modal-header { display: flex; align-items: center; gap: 8px; padding: 16px; border-bottom: 1px solid var(--assistant-border); background: var(--bg-color); border-radius: 12px 12px 0 0; }
.search-modal-header input { flex: 1; padding: 8px 12px; border: 1px solid var(--assistant-border); border-radius: 6px; font-size: 16px; }
#search-status { padding: 8px 16px; font-size: 0.85rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
#search-results { flex: 1; overflow-y: auto; padding: 16px; }
.search-result { margin-bottom: 16px; border-radius: 8px; overflow: hidden; box-shadow: 0 1px 3px rgba(0,0,0,0.1); }
.search-result a { display: block; text-decoration: none; color: inherit; }
.search-result a:hover { background: rgba(25, 118, 210, 0.05); }
.search-result-page { padding: 6px 12px; background: rgba(0,0,0,0.03); font-size: 0.8rem; color: var(--text-muted); border-bottom: 1px solid rgba(0,0,0,0.06); }
.search-result-content { padding: 12px; }
.search-result mark { background: #fff59d; padding: 1px 2px; border-radius: 2px; }
@media (max-width: 600px) { body { padding: 8px; } .message, .index-item { border-radius: 8px; } .message-content, .index-item-content { padding: 12px; } pre { font-size: 0.8rem; padding: 8px; } #search-box input { width: 120px; } #search-modal[open] { width: 95vw; height: 90vh; } }
</style>
</head>
<body>
    <div class="container">
        <h1><a href="index.html" style="color: inherit; text-decoration: none;">Claude Code transcript</a> - page 4/4</h1>
        

<div class="pagination">
<a href="index.html" class="index-link">Index</a>
<a href="page-003.html">&larr; Prev</a>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<a href="page-003.html">3</a>
<span class="current">4</span>
<span class="disabled">Next &rarr;</span>
</div>

        
<div class="message user" id="msg-2025-12-14T23-07-53-811Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T23-07-53-811Z" class="timestamp-link"><time datetime="2025-12-14T23:07:53.811Z" data-timestamp="2025-12-14T23:07:53.811Z">2025-12-14T23:07:53.811Z</time></a></div><div class="message-content">
<div class="user-content"><p>We have access to the iSeq and NovaSeq. I am not quite as interested in Nanopore or pacbio due to costs and the lower quality of our nucleic acid. Can you give a pros and cons for the UMI. Yes I am interested in publication and also potential an R21 application. In particular the PCR based approaches might find use in LMIC. However, I do not want to sacrifice what we can do in the US and still want advancements towards higher cost solutions that i can compelte in my lab. But hopefully there is an overlap between high-income and LMIC solutions here. Also what can we do with current publically available data and not rely on   - Less database bias (you'll build your own reference)</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-09-30-430Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-09-30-430Z" class="timestamp-link"><time datetime="2025-12-14T23:09:30.430Z" data-timestamp="2025-12-14T23:09:30.430Z">2025-12-14T23:09:30.430Z</time></a></div><div class="message-content">
<div class="assistant-text"><h2>UMI Analysis: Pros and Cons for Your Application</h2>
<h3>What UMIs Actually Give You</h3>
<pre><code>Without UMI:
  Original molecules â†’ PCR amplification â†’ Sequencing
                            â†“
  10 copies of molecule A â†’ 1000 reads (100x amplification)
  10 copies of molecule B â†’ 100 reads (10x amplification)
                            â†“
  Relative abundance: 91% A, 9% B (WRONG - should be 50/50)

With UMI:
  Original molecules â†’ Tag with unique barcode â†’ PCR â†’ Sequencing
                            â†“
  Molecule A-UMI1 â†’ 100 reads â†’ collapse to 1
  Molecule A-UMI2 â†’ 150 reads â†’ collapse to 1
  ...
  Molecule A-UMI10 â†’ 80 reads â†’ collapse to 1
  Molecule B-UMI1 â†’ 10 reads â†’ collapse to 1
  ...
  Molecule B-UMI10 â†’ 12 reads â†’ collapse to 1
                            â†“
  Count UMIs: 10 for A, 10 for B = 50/50 (CORRECT)
</code></pre>
<h3>Pros</h3>
<table>
<thead>
<tr>
<th>Benefit</th>
<th>Relevance to your project</th>
<th>Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>True molecule counting</strong></td>
<td>Absolute quantification without qPCR</td>
<td>High - you have spike-ins, UMIs make them work better</td>
</tr>
<tr>
<td><strong>PCR bias correction</strong></td>
<td>GC-rich/poor sequences amplify differently</td>
<td>High - Gardnerella and Lactobacillus have different GC content</td>
</tr>
<tr>
<td><strong>Chimera elimination</strong></td>
<td>PCR chimeras are major problem in amplicon studies</td>
<td>High - your multi-gene approach compounds this risk</td>
</tr>
<tr>
<td><strong>Strain deconvolution</strong></td>
<td>Distinguish strain mixtures in same sample</td>
<td>Very high - your Fig 3 shows strain structure matters</td>
</tr>
<tr>
<td><strong>Error correction</strong></td>
<td>Consensus from multiple reads of same molecule</td>
<td>Medium - Illumina already high quality</td>
</tr>
<tr>
<td><strong>Low-template accuracy</strong></td>
<td>Critical when few molecules present</td>
<td>Medium - FGT generally high biomass</td>
</tr>
</tbody>
</table>
<h3>Cons</h3>
<table>
<thead>
<tr>
<th>Drawback</th>
<th>Mitigation</th>
<th>Severity</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Increased sequencing depth needed</strong></td>
<td>Need ~10-25x coverage per UMI for consensus</td>
<td>Moderate - NovaSeq handles this</td>
</tr>
<tr>
<td><strong>More expensive primers</strong></td>
<td>~$50-100 more per primer pair</td>
<td>Low - one-time cost</td>
</tr>
<tr>
<td><strong>Bioinformatics complexity</strong></td>
<td>Need UMI processing pipeline</td>
<td>Moderate - tools exist (DADA2-UMI, AmpUMI)</td>
</tr>
<tr>
<td><strong>Reduced effective read depth</strong></td>
<td>Collapse reads â†’ fewer data points</td>
<td>Moderate - offset by accuracy</td>
</tr>
<tr>
<td><strong>Requires higher input DNA</strong></td>
<td>Need enough molecules for UMI diversity</td>
<td>Low - FGT samples generally good</td>
</tr>
<tr>
<td><strong>Index hopping risk on NovaSeq</strong></td>
<td>UMIs can help detect this</td>
<td>Actually a pro</td>
</tr>
</tbody>
</table>
<h3>Recommendation: Tiered UMI Strategy</h3>
<pre><code>FULL UMI (worth the investment):
â”œâ”€â”€ cpn60 - strain resolution is your goal
â””â”€â”€ rpoB - orthogonal strain validation

NO UMI (not worth complexity):
â”œâ”€â”€ 16S V4 - cross-study compatibility more important
â”œâ”€â”€ 16S V1-V3 - species-level sufficient
â””â”€â”€ Functional genes - presence/absence or relative quantity sufficient
</code></pre>
<p><strong>Rationale:</strong> UMIs add most value where you need <strong>strain-level precision</strong> and <strong>absolute molecule counting</strong>. For functional genes, you care about "is nanH present and at what level" - relative quantification normalized to spike-ins is sufficient.</p>
<h3>Cost Impact</h3>
<table>
<thead>
<tr>
<th>Component</th>
<th>Without UMI</th>
<th>With UMI</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primer synthesis</td>
<td>~$200/pair</td>
<td>~$300/pair</td>
<td>+$100</td>
</tr>
<tr>
<td>Sequencing depth needed</td>
<td>30-50K reads</td>
<td>100-150K reads</td>
<td>2-3x</td>
</tr>
<tr>
<td>Bioinformatics time</td>
<td>Standard</td>
<td>+20%</td>
<td>Personnel</td>
</tr>
</tbody>
</table>
<p>For cpn60 + rpoB only: <strong>~$200 primer cost + ~$10-15/sample additional sequencing</strong></p>
<hr />
<h2>High-Income vs. LMIC Overlap: The Dual-Use Design</h2>
<p>This is where your platform gets strategic. You can design a single primer/protocol foundation that scales in both directions:</p>
<pre><code>â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    DUAL-USE PLATFORM ARCHITECTURE                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚                        SHARED FOUNDATION                                â”‚
â”‚                    (Same primers, same targets)                         â”‚
â”‚                              â”‚                                          â”‚
â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                    â”‚
â”‚         â–¼                                         â–¼                    â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”               â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”‚
â”‚  â”‚   HIGH-RESOURCE     â”‚               â”‚      LMIC           â”‚         â”‚
â”‚  â”‚   (Wash U, Ragon)   â”‚               â”‚   (Durban, etc.)    â”‚         â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤               â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â”‚ â€¢ Full multi-ampliconâ”‚              â”‚ â€¢ Targeted qPCR     â”‚         â”‚
â”‚  â”‚   panel (6-8 genes) â”‚               â”‚   panel (4-6 targets)â”‚        â”‚
â”‚  â”‚ â€¢ UMI for strain    â”‚               â”‚ â€¢ Same primer       â”‚         â”‚
â”‚  â”‚   resolution        â”‚               â”‚   binding sites     â”‚         â”‚
â”‚  â”‚ â€¢ NovaSeq depth     â”‚               â”‚ â€¢ QuantStudio/CFX96 â”‚         â”‚
â”‚  â”‚ â€¢ Full bioinformaticsâ”‚              â”‚ â€¢ Simple Ct analysisâ”‚         â”‚
â”‚  â”‚ â€¢ Research discovery â”‚              â”‚ â€¢ Clinical/field useâ”‚         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â”‚ Cost: ~$75-100/sampleâ”‚              â”‚ Cost: ~$15-25/sampleâ”‚         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜               â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â”‚
â”‚                                                                         â”‚
â”‚                        KEY INSIGHT:                                     â”‚
â”‚         Same primer binding sites enable both applications             â”‚
â”‚         Sequencing primers â†’ qPCR primers with minimal redesign        â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
</code></pre>
<h3>How This Works Technically</h3>
<p><strong>Design amplicon primers with qPCR in mind:</strong></p>
<pre><code>Amplicon primer (for sequencing):
5'-[Illumina adapter]-[optional UMI]-[GENE-SPECIFIC SEQUENCE]-3'
                                     â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
                                     This part = qPCR primer

qPCR primer (for LMIC):
5'-[GENE-SPECIFIC SEQUENCE]-3'
   â””â”€â”€ Same binding site, no adapter/UMI

Probe (for qPCR):
5'-[FAM]-[Internal probe sequence]-[BHQ]-3'
         â””â”€â”€ Designed within amplicon
</code></pre>
<p><strong>Result:</strong> Your sequencing validation directly validates LMIC qPCR performance.</p>
<hr />
<h2>Leveraging Public Data: What's Available Now</h2>
<p>You asked what you can do without building your own reference. Here's the landscape:</p>
<h3>Available Databases</h3>
<table>
<thead>
<tr>
<th>Database</th>
<th>Content</th>
<th>FGT coverage</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>cpnDB</strong></td>
<td>~29K cpn60 sequences</td>
<td>Good for common taxa</td>
<td>Canadian/European bias; certificate expired (maintenance?)</td>
</tr>
<tr>
<td><strong>VOGUE</strong></td>
<td>Vaginal cpn60 reference</td>
<td>Excellent for vaginal</td>
<td>Canadian population only</td>
</tr>
<tr>
<td><strong>SILVA</strong></td>
<td>16S/18S/23S</td>
<td>Comprehensive</td>
<td>No cpn60, no functional genes</td>
</tr>
<tr>
<td><strong>GreenGenes2</strong></td>
<td>16S with WGS backbone</td>
<td>Good</td>
<td>No cpn60</td>
</tr>
<tr>
<td><strong>GTDB</strong></td>
<td>Genome-based taxonomy</td>
<td>Excellent</td>
<td>Requires genome, not amplicon</td>
</tr>
<tr>
<td><strong>UniProt/NCBI</strong></td>
<td>Functional genes</td>
<td>Variable</td>
<td>Need manual curation per gene</td>
</tr>
</tbody>
</table>
<h3>What You Can Do Now (Before Isolate Sequencing)</h3>
<p><strong>1. cpn60 Analysis Using VOGUE + cpnDB</strong></p>
<pre><code>Available pipeline (Hill lab):
â”œâ”€â”€ MiSeq-compatible protocol exists
â”œâ”€â”€ VOGUE reference assembly for vaginal samples
â”œâ”€â”€ cpnDB_nr for broader classification
â”œâ”€â”€ Published in multiple vaginal microbiome papers
â””â”€â”€ Limitation: North American reference, may miss SA-specific variants
</code></pre>
<p><strong>Validation approach:</strong>
- Run cpn60 on subset with existing 16S data
- Compare species calls
- Flag discordances for investigation
- Discordances = either database gap OR novel taxon</p>
<p><strong>2. rpoB: Build from Public Genomes</strong></p>
<pre><code>Strategy:
1. Download all Lactobacillus genomes from NCBI (&gt;500 available)
2. Download all Gardnerella genomes (~100 available)
3. Download Prevotella, Sneathia, Megasphaera genomes
4. Extract rpoB sequences computationally
5. Align, design primers to conserved regions
6. Build classification database

Tools: Prokka for annotation, MUSCLE for alignment, DegePrime for primers
Timeline: 2-3 weeks of bioinformatics work
</code></pre>
<p><strong>3. Functional Genes: NCBI + Literature Curation</strong></p>
<table>
<thead>
<tr>
<th>Gene</th>
<th>Public data availability</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>nanH</strong></td>
<td>Good - well-characterized in Gardnerella</td>
<td>Multiple papers on variants; crystal structures exist</td>
</tr>
<tr>
<td><strong>vly</strong></td>
<td>Good - characterized virulence factor</td>
<td>Sequence variation documented</td>
</tr>
<tr>
<td><strong>ily</strong></td>
<td>Good - L. iners specific</td>
<td>Limited strain diversity data</td>
</tr>
<tr>
<td><strong>speA/odc</strong></td>
<td>Moderate - scattered across genera</td>
<td>Need broader search</td>
</tr>
<tr>
<td><strong>ldcC</strong></td>
<td>Moderate - same as above</td>
<td>Biogenic amine pathway well-studied</td>
</tr>
<tr>
<td><strong>ldhD/ldhL</strong></td>
<td>Excellent - metabolic genes</td>
<td>Well-characterized in Lactobacillus</td>
</tr>
</tbody>
</table>
<p><strong>Workflow for each functional gene:</strong></p>
<pre><code>1. Literature search: Find characterized sequences
2. NCBI search: Download all annotated sequences
3. Expand with BLAST: Find unannotated homologs
4. Align: Identify conserved regions for primers
5. Design: Broad primers capturing known diversity
6. Validate in silico: Test against FGT genomes
</code></pre>
<h3>The Hybrid Strategy</h3>
<pre><code>Phase 1: Use public databases (Now - Month 6)
â”œâ”€â”€ cpn60: VOGUE + cpnDB
â”œâ”€â”€ rpoB: Built from NCBI genomes
â”œâ”€â”€ Functional genes: Curated from NCBI/UniProt
â””â”€â”€ Validation: Cross-reference with your 16S V4 data

Phase 2: Augment with your isolates (Month 6+)
â”œâ”€â”€ Sequence 600 isolates (as culturomics proceeds)
â”œâ”€â”€ Extract cpn60, rpoB, functional genes
â”œâ”€â”€ Add to databases
â”œâ”€â”€ Re-classify samples with augmented DB
â””â”€â”€ Identify SA-specific variants/taxa

Phase 3: Public resource (Month 12+)
â”œâ”€â”€ FRESH-DB: Combined public + your sequences
â”œâ”€â”€ Validated against South African population
â”œâ”€â”€ Published, deposited, citable
</code></pre>
<hr />
<h2>R21 Concept: Multi-Amplicon Platform for FGT Microbiome</h2>
<p>Here's a sketch of how this could be structured:</p>
<h3>Title Options</h3>
<ul>
<li>"A Multi-Amplicon Platform for High-Resolution Female Genital Tract Microbiome Profiling"</li>
<li>"Strain-Level FGT Microbiome Profiling Through Integrated Multi-Gene Amplicon Sequencing"</li>
<li>"Cost-Effective, Scalable Microbiome Profiling for HIV Acquisition Risk Assessment"</li>
</ul>
<h3>Specific Aims (R21 format - exploratory/developmental)</h3>
<p><strong>Aim 1: Develop and validate a multi-amplicon sequencing platform for species and strain-level FGT microbiome profiling</strong></p>
<pre><code>Aim 1.1: Optimize multiplexed amplicon panel
â”œâ”€â”€ Taxonomic: 16S V4, 16S V1-V3, cpn60 (UMI), rpoB (UMI)
â”œâ”€â”€ Functional: nanH, vly, ily, ldhD, speA, ldcC
â”œâ”€â”€ Optimize multiplexing pools
â”œâ”€â”€ Validate with mock communities
â””â”€â”€ Compare to metagenomic gold standard (collaborator samples)

Aim 1.2: Develop bioinformatics pipeline for multi-marker integration
â”œâ”€â”€ UMI-based error correction
â”œâ”€â”€ Multi-marker taxonomic concordance
â”œâ”€â”€ Functional gene quantification
â”œâ”€â”€ Absolute abundance (spike-in normalization)
â””â”€â”€ Composite scoring (inflammation potential, protection score)

Aim 1.3: Build South African FGT reference database
â”œâ”€â”€ Extract sequences from cultured isolates
â”œâ”€â”€ Validate against public databases
â”œâ”€â”€ Identify population-specific variants
â””â”€â”€ Public deposition
</code></pre>
<p><strong>Aim 2: Demonstrate platform performance in the FRESH cohort</strong></p>
<pre><code>Aim 2.1: Profile subset of FRESH samples (n=500)
â”œâ”€â”€ Samples selected across cervicotypes
â”œâ”€â”€ Include HIV seroconverters and matched controls
â”œâ”€â”€ Generate full multi-amplicon profiles

Aim 2.2: Validate against existing data
â”œâ”€â”€ Compare to 16S V4 cervicotype assignments
â”œâ”€â”€ Compare to collaborator metagenomic data
â”œâ”€â”€ Correlate functional scores with cytokine data
â””â”€â”€ Test association with HIV acquisition

Aim 2.3: Develop field-deployable qPCR derivative
â”œâ”€â”€ Convert sequencing primers to qPCR format
â”œâ”€â”€ Validate on subset of samples
â”œâ”€â”€ Establish protocol for LMIC deployment
</code></pre>
<h3>Innovation Statement</h3>
<pre><code>This proposal addresses critical limitations in current FGT microbiome profiling:

1. Species/strain resolution: 16S rRNA cannot distinguish Gardnerella species 
   or Lactobacillus strains. Our multi-marker approach (cpn60 + rpoB) provides 
   species-level resolution validated by marker concordance.

2. Functional readouts without metagenomics: Current functional profiling 
   requires expensive shotgun metagenomics. Our targeted functional amplicons 
   provide direct quantification of inflammation-associated genes at amplicon 
   sequencing costs.

3. Absolute quantification: Standard amplicon approaches generate only relative 
   abundance. Our spike-in normalized, UMI-tagged approach provides absolute 
   molecule counts enabling comparison across samples with different biomass.

4. Scalability to LMIC: The same primer binding sites validated for sequencing 
   can be directly translated to qPCR for low-resource settings, enabling 
   research and eventual clinical translation in sub-Saharan Africa.

5. Population-specific reference: Existing databases are biased toward 
   North American/European populations. Our South African reference database 
   will enable accurate profiling of the populations most affected by HIV.
</code></pre>
<h3>Budget Justification (~$275K/year for 2 years = $550K total)</h3>
<pre><code>Year 1: Development and Validation
â”œâ”€â”€ Personnel: Postdoc (50%), Technician (25%)     $150K
â”œâ”€â”€ Primer synthesis and optimization               $15K
â”œâ”€â”€ Mock community generation/purchase              $5K
â”œâ”€â”€ Sequencing (validation samples, n=200)          $30K
â”œâ”€â”€ Supplies (library prep, extraction)             $25K
â”œâ”€â”€ Isolate sequencing (200 isolates)               $40K
â””â”€â”€ Computational (cloud, storage)                  $10K
                                            Total: $275K

Year 2: Application and Deployment
â”œâ”€â”€ Personnel: Postdoc (50%), Technician (25%)     $150K
â”œâ”€â”€ Sequencing (FRESH samples, n=500)              $50K
â”œâ”€â”€ qPCR development and validation                $20K
â”œâ”€â”€ Supplies                                        $25K
â”œâ”€â”€ Isolate sequencing (200 more)                  $20K
â””â”€â”€ Publication costs, database hosting            $10K
                                            Total: $275K
</code></pre>
<h3>Significance for LMIC</h3>
<pre><code>HIV disproportionately affects women in sub-Saharan Africa, where vaginal 
microbiota-associated inflammation increases acquisition risk 4-fold. Current 
microbiome profiling approaches are too expensive and technically demanding 
for routine use in these settings.

This platform addresses the need for:

1. Research tools: Enable large-scale studies in African cohorts without 
   prohibitive metagenomics costs

2. Clinical translation path: qPCR derivative allows risk stratification 
   in clinical settings with basic molecular biology infrastructure

3. Local reference data: South African-specific database improves accuracy 
   for the populations where this work matters most

4. Capacity building: Simpler protocols enable local laboratories to 
   participate in microbiome research
</code></pre>
<hr />
<h2>Summary: Recommended Path Forward</h2>
<h3>Immediate Actions (Months 1-3)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Approach</th>
</tr>
</thead>
<tbody>
<tr>
<td>cpn60 primers</td>
<td>Obtain H279p/H280p; design UMI-tagged versions</td>
</tr>
<tr>
<td>rpoB primers</td>
<td>Design de novo from NCBI genomes; DPO format</td>
</tr>
<tr>
<td>Functional gene primers</td>
<td>Curate from NCBI; design using DegePrime</td>
</tr>
<tr>
<td>Reference databases</td>
<td>Download VOGUE, cpnDB; build rpoB DB from genomes</td>
</tr>
<tr>
<td>Pipeline planning</td>
<td>Specify UMI processing, multi-marker integration</td>
</tr>
</tbody>
</table>
<h3>Validation Phase (Months 3-6)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Samples</th>
<th>Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mock communities</td>
<td>Defined mixtures</td>
<td>Expected composition</td>
</tr>
<tr>
<td>Archived FRESH</td>
<td>n=100 with 16S V4</td>
<td>Concordance with existing data</td>
</tr>
<tr>
<td>Isolates</td>
<td>n=50 sequenced</td>
<td>Full gene extraction</td>
</tr>
</tbody>
</table>
<h3>Scale-up (Months 6-18)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full FRESH profiling</td>
<td>n=3600 (or tiered subset)</td>
</tr>
<tr>
<td>Reference database</td>
<td>Integrated with isolate sequences</td>
</tr>
<tr>
<td>Methods publication</td>
<td>Platform paper</td>
</tr>
<tr>
<td>R21 submission</td>
<td>Based on validation data</td>
</tr>
</tbody>
</table>
<h3>Parallel qPCR Development (Months 6-12)</h3>
<table>
<thead>
<tr>
<th>Task</th>
<th>Scope</th>
</tr>
</thead>
<tbody>
<tr>
<td>Convert primers</td>
<td>Sequencing â†’ qPCR format</td>
</tr>
<tr>
<td>Optimize multiplex</td>
<td>4-6 target panel</td>
</tr>
<tr>
<td>Validate</td>
<td>Against sequencing results</td>
</tr>
<tr>
<td>Protocol for LMIC</td>
<td>Simple, robust, documented</td>
</tr>
</tbody>
</table>
<hr />
<h2>Questions to Finalize</h2>
<ol>
<li>
<p><strong>R21 timing?</strong> Standard cycle or NOSI-related opportunity?</p>
</li>
<li>
<p><strong>Collaborator metagenomics samples available for validation?</strong> Would help establish "gold standard" comparison.</p>
</li>
<li>
<p><strong>Mock community source?</strong> Zymo vaginal mock? Or custom from your isolates?</p>
</li>
<li>
<p><strong>Functional gene final list?</strong> My Tier 1 (nanH, vly, speA, ldcC, ldhD) + ily/ldhL?</p>
</li>
<li>
<p><strong>Publication strategy?</strong> Methods paper first, or combined with initial FRESH findings?</p>
</li>
</ol></div></div></div>
<div class="message user" id="msg-2025-12-14T23-15-48-971Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T23-15-48-971Z" class="timestamp-link"><time datetime="2025-12-14T23:15:48.971Z" data-timestamp="2025-12-14T23:15:48.971Z">2025-12-14T23:15:48.971Z</time></a></div><div class="message-content">
<div class="user-content"><p>I like this overall strategy. Can you save it as a new markdown to this file. Also can you search the web and invesitage the R21 or other funding possibilities? I just picked R21 as it seemed like a good fit, but lets be more open to other potential funders. I agree to your functional gene list for now. I want to do a methods paper first. the fresh study will take a long time to get through and we want this as a foundational method</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-15-52-351Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-15-52-351Z" class="timestamp-link"><time datetime="2025-12-14T23:15:52.351Z" data-timestamp="2025-12-14T23:15:52.351Z">2025-12-14T23:15:52.351Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>I'll save the strategy document and then search for funding opportunities.</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-14-069Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-14-069Z" class="timestamp-link"><time datetime="2025-12-14T23:17:14.069Z" data-timestamp="2025-12-14T23:17:14.069Z">2025-12-14T23:17:14.069Z</time></a></div><div class="message-content"><div class="file-tool write-tool" data-tool-id="toolu_01TfZz9yFNyRrTyznv1SNhtX">
<div class="file-tool-header write-header"><span class="file-tool-icon">ğŸ“</span> Write <span class="file-tool-path">multi-amplicon-platform-strategy.md</span></div>
<div class="file-tool-fullpath">/Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md</div>
<div class="truncatable"><div class="truncatable-content"><pre class="file-content"># Multi-Amplicon FGT Microbiome Profiling Platform

## Strategic Vision

Build a next-generation amplicon platform that extracts metagenomic-level insights without metagenomics costs, enabling both high-resource research and LMIC field deployment.

### Goals
- Species/strain-level taxonomic resolution
- Functional gene quantification
- Absolute abundance measurement
- Cross-study compatibility
- Scalable from NovaSeq to field qPCR

---

## Platform Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚           MULTI-AMPLICON FGT PROFILING PLATFORM                        â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚  EXISTING ASSETS                                                        â”‚
â”‚  â”œâ”€â”€ 16S V4 (515F/806R) - Earth Microbiome Project                     â”‚
â”‚  â”œâ”€â”€ 16S V1-V3 (Ravel validated)                                       â”‚
â”‚  â”œâ”€â”€ Zymo spike-ins (absolute quantification)                          â”‚
â”‚  â””â”€â”€ ITS2 (fungal - already running)                                   â”‚
â”‚                                                                         â”‚
â”‚  NEW DEVELOPMENT                                                        â”‚
â”‚  â”œâ”€â”€ cpn60 UT (species resolution, Gardnerella)                        â”‚
â”‚  â”œâ”€â”€ rpoB (orthogonal validation, Lactobacillus)                       â”‚
â”‚  â””â”€â”€ Functional gene panel (mechanistic readouts)                      â”‚
â”‚                                                                         â”‚
â”‚  NOVEL TECH/INFORMATICS                                                 â”‚
â”‚  â”œâ”€â”€ UMI integration for strain deconvolution                          â”‚
â”‚  â”œâ”€â”€ Multi-marker taxonomic concordance                                â”‚
â”‚  â”œâ”€â”€ Functional scoring algorithms                                     â”‚
â”‚  â””â”€â”€ South African reference database                                  â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Amplicon Panel Specification

### Taxonomic Amplicons

| Amplicon | Status | Purpose | UMI | Notes |
|----------|--------|---------|-----|-------|
| 16S V4 | Have (EMP 515F/806R) | Cross-study compatibility | No | Standard protocol |
| 16S V1-V3 | Have (Ravel) | Lactobacillus resolution | No | Validated for vaginal |
| cpn60 UT | Need (H279p/H280p) | Gardnerella species, strain | Yes | ~550bp |
| rpoB | Design de novo | Orthogonal validation | Yes | ~350-550bp, DPO format |

### Functional Gene Amplicons

**Tier 1: Core Panel (directly supported by FRESH preliminary data)**

| Gene | Target Organism(s) | Biological Function | HIV Relevance |
|------|-------------------|---------------------|---------------|
| nanH1/nanH2 | Gardnerella sialidases | Mucin degradation | Epithelial barrier disruption, HIV target cell exposure |
| vly | Gardnerella vaginolysin | Cytolysin, cell lysis | PAMP release, TLR4 activation, inflammation |
| speA/odc | Multiple (ornithine decarboxylase) | Putrescine synthesis | Biogenic amine, pro-inflammatory |
| ldcC | Multiple (lysine decarboxylase) | Cadaverine synthesis | Biogenic amine, pro-inflammatory |
| ldhD | L. crispatus D-lactate dehydrogenase | D-lactic acid production | Protective, acidification |

**Tier 2: Extended Panel**

| Gene | Target Organism(s) | Biological Function | HIV Relevance |
|------|-------------------|---------------------|---------------|
| ily | L. iners inerolysin | Cholesterol-dependent cytolysin | Epithelial damage, L. iners virulence |
| ldhL | All Lactobacillus L-lactate dehydrogenase | L-lactic acid production | Less protective than D-lactate; ratio informative |

---

## UMI Strategy

### Recommendation: Tiered UMI Application

**FULL UMI (worth the investment):**
- cpn60 - strain resolution is primary goal
- rpoB - orthogonal strain validation

**NO UMI (not worth complexity):**
- 16S V4 - cross-study compatibility more important
- 16S V1-V3 - species-level sufficient
- Functional genes - presence/absence or relative quantity sufficient

### UMI Benefits for cpn60/rpoB
- True molecule counting (absolute quantification)
- PCR bias correction (GC content differences)
- Chimera elimination (&lt;0.02% rate)
- Strain mixture deconvolution
- Error correction via consensus

### UMI Cost Impact
- Primer synthesis: +$100/pair
- Sequencing depth: 2-3x increase (100-150K reads vs 30-50K)
- Per sample additional cost: ~$10-15

---

## Dual-Use Design: High-Resource and LMIC

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    DUAL-USE PLATFORM ARCHITECTURE                       â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚                        SHARED FOUNDATION                                â”‚
â”‚                    (Same primers, same targets)                         â”‚
â”‚                              â”‚                                          â”‚
â”‚         â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”´â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”                    â”‚
â”‚         â–¼                                         â–¼                    â”‚
â”‚  â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”               â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”         â”‚
â”‚  â”‚   HIGH-RESOURCE     â”‚               â”‚      LMIC           â”‚         â”‚
â”‚  â”‚   (Wash U, Ragon)   â”‚               â”‚   (Durban, etc.)    â”‚         â”‚
â”‚  â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤               â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â”‚ â€¢ Full multi-ampliconâ”‚              â”‚ â€¢ Targeted qPCR     â”‚         â”‚
â”‚  â”‚   panel (6-8 genes) â”‚               â”‚   panel (4-6 targets)â”‚        â”‚
â”‚  â”‚ â€¢ UMI for strain    â”‚               â”‚ â€¢ Same primer       â”‚         â”‚
â”‚  â”‚   resolution        â”‚               â”‚   binding sites     â”‚         â”‚
â”‚  â”‚ â€¢ NovaSeq depth     â”‚               â”‚ â€¢ QuantStudio/CFX96 â”‚         â”‚
â”‚  â”‚ â€¢ Full bioinformaticsâ”‚              â”‚ â€¢ Simple Ct analysisâ”‚         â”‚
â”‚  â”‚ â€¢ Research discovery â”‚              â”‚ â€¢ Clinical/field useâ”‚         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â”‚ Cost: ~$75-100/sampleâ”‚              â”‚ Cost: ~$15-25/sampleâ”‚         â”‚
â”‚  â”‚                     â”‚               â”‚                     â”‚         â”‚
â”‚  â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜               â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜         â”‚
â”‚                                                                         â”‚
â”‚                        KEY INSIGHT:                                     â”‚
â”‚         Same primer binding sites enable both applications             â”‚
â”‚         Sequencing primers â†’ qPCR primers with minimal redesign        â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Technical Implementation

```
Amplicon primer (for sequencing):
5&#39;-[Illumina adapter]-[optional UMI]-[GENE-SPECIFIC SEQUENCE]-3&#39;
                                     â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
                                     This part = qPCR primer

qPCR primer (for LMIC):
5&#39;-[GENE-SPECIFIC SEQUENCE]-3&#39;
   â””â”€â”€ Same binding site, no adapter/UMI

Probe (for qPCR):
5&#39;-[FAM]-[Internal probe sequence]-[BHQ]-3&#39;
         â””â”€â”€ Designed within amplicon
```

---

## Reference Database Strategy

### Phase 1: Public Databases (Immediate)

| Database | Use | Limitations |
|----------|-----|-------------|
| cpnDB + VOGUE | cpn60 classification | Canadian/European bias |
| NCBI genomes | rpoB extraction, functional genes | Need curation |
| SILVA | 16S backup | Standard |
| GreenGenes2 | 16S primary | Standard |

### Phase 2: FRESH-DB (With Isolate Sequencing)

From 600 cultured isolates:
- Extract full cpn60, rpoB, functional genes
- Add to databases
- Validate population-specific variants
- Public deposition

### Workflow for Public Data

```
rpoB database construction:
1. Download all Lactobacillus genomes from NCBI (&gt;500)
2. Download Gardnerella, Prevotella, Sneathia, Megasphaera genomes
3. Extract rpoB sequences computationally (Prokka)
4. Align with MUSCLE/MAFFT
5. Design primers to conserved regions (DegePrime)
6. Build classification database

Functional gene curation:
1. Literature search for characterized sequences
2. NCBI/UniProt download of annotated sequences
3. BLAST expansion for unannotated homologs
4. Alignment and primer design
5. In silico validation against FGT genomes
```

---

## Bioinformatics Pipeline Architecture

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    MULTI-AMPLICON ANALYSIS PIPELINE                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                         â”‚
â”‚  INPUT: Multiplexed amplicon reads                                      â”‚
â”‚         â†“                                                               â”‚
â”‚  DEMULTIPLEXING                                                         â”‚
â”‚  â”œâ”€â”€ By sample (dual index)                                            â”‚
â”‚  â”œâ”€â”€ By amplicon (primer sequence)                                     â”‚
â”‚  â””â”€â”€ By molecule (UMI, for cpn60/rpoB)                                 â”‚
â”‚         â†“                                                               â”‚
â”‚  AMPLICON-SPECIFIC PROCESSING                                           â”‚
â”‚  â”œâ”€â”€ 16S V4: DADA2 â†’ GreenGenes2                                       â”‚
â”‚  â”œâ”€â”€ 16S V1-V3: DADA2 â†’ SILVA + custom Lactobacillus DB                â”‚
â”‚  â”œâ”€â”€ cpn60: UMI consensus â†’ cpnDB + FRESH-DB                           â”‚
â”‚  â”œâ”€â”€ rpoB: UMI consensus â†’ Custom DB (build from genomes)              â”‚
â”‚  â””â”€â”€ Functional: Quantify â†’ Normalize to spike-in                      â”‚
â”‚         â†“                                                               â”‚
â”‚  INTEGRATION                                                            â”‚
â”‚  â”œâ”€â”€ Taxonomic concordance scoring                                     â”‚
â”‚  â”œâ”€â”€ Spike-in normalization (absolute abundance)                       â”‚
â”‚  â”œâ”€â”€ Functional gene quantification                                    â”‚
â”‚  â””â”€â”€ Composite scores (Inflammation, Protection, Risk)                 â”‚
â”‚         â†“                                                               â”‚
â”‚  OUTPUT                                                                 â”‚
â”‚  â”œâ”€â”€ Per-sample: Taxonomy + Absolute abundance + Functional scores     â”‚
â”‚  â”œâ”€â”€ Per-cohort: Integration with metadata, outcomes                   â”‚
â”‚  â””â”€â”€ QC reports: Concordance, spike-in recovery, controls              â”‚
â”‚                                                                         â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### Innovation Components

**1. Multi-Marker Taxonomic Concordance**
```
16S V4    â”€â”
16S V1-V3 â”€â”¼â”€â†’ Concordance analysis â”€â†’ Confidence-weighted taxonomy
cpn60     â”€â”¤                         â”€â†’ Novel taxa flagging
rpoB      â”€â”˜                         â”€â†’ Database gap identification
```

**2. Functional Scoring**
```
Inflammation Potential Score = f(nanH, vly, speA, ldcC)
Protection Score = f(ldhD, total_Lactobacillus, L.crispatus_abundance)
Risk Index = Inflammation_Score / Protection_Score
```

---

## Cost Model

### Per-Sample Sequencing Costs (New Components)

| Component | Reads needed | Cost estimate |
|-----------|--------------|---------------|
| 16S V1-V3 | 50K | ~$10-15 |
| cpn60 + UMI | 100-150K | ~$15-20 |
| rpoB + UMI | 100K | ~$12-15 |
| Functional panel (7 genes) | 100K total | ~$20-30 |
| **Total additional per sample** | | **~$55-80** |

### One-Time Costs

| Item | Cost |
|------|------|
| Primer synthesis (including UMI versions) | ~$5-10K |
| Validation/optimization | ~$20-30K |
| Mock community development | ~$5K |

### Comparison to Metagenomics

| Approach | Per sample | 3600 samples |
|----------|-----------|--------------|
| This platform | ~$75-100 | ~$300K |
| Metagenomics | ~$400-600 | ~$1.5-2M |

---

## Development Timeline

### Phase 1: Primer Development (Months 1-4)
- Obtain/synthesize cpn60 primers (+ UMI version)
- Design rpoB primers (DPO format, + UMI version)
- Design functional gene primers (nanH, vly, speA, ldcC, ldhD, ily, ldhL)
- In silico validation against databases
- Build rpoB database from NCBI genomes
- Curate functional gene sequences

### Phase 2: Wet Lab Validation (Months 4-8)
- Test on mock communities
- Test on 50-100 archived FRESH samples with known 16S
- Optimize multiplexing pools
- Validate spike-in quantification
- Compare to existing 16S V4 data
- Establish SOPs

### Phase 3: Pipeline Development (Months 4-10, parallel)
- UMI processing module
- Multi-marker integration algorithm
- Concordance scoring
- Functional quantification
- FRESH-DB construction framework
- Visualization/reporting

### Phase 4: Methods Publication (Months 10-14)
- Complete validation dataset
- Write methods paper
- Submit to microbiome/methods journal
- Public code/database release

### Phase 5: Scale-up to FRESH (Months 12-24+)
- Process samples in batches
- Integrate with host data (cytokines, flow cytometry, scRNAseq)
- Correlate with HIV outcomes
- Feed candidates to model systems (Aim 2)

### Parallel: qPCR Development (Months 6-12)
- Convert primers to qPCR format
- Optimize multiplex panel (4-6 targets)
- Validate against sequencing results
- Document protocol for LMIC deployment

---

## Publication Strategy

### Methods Paper (Primary - submit first)

**Target journals:**
- Microbiome
- mSystems
- Nature Methods (if innovation is strong enough)
- Genome Biology

**Title options:**
- &#34;A Multi-Amplicon Platform for High-Resolution Female Genital Tract Microbiome Profiling&#34;
- &#34;Integrated Multi-Gene Amplicon Sequencing for Species-Level Vaginal Microbiome Characterization&#34;

**Key elements:**
- Platform description and validation
- Comparison to 16S-only and metagenomics
- Multi-marker concordance analysis
- Functional gene quantification validation
- Spike-in normalization for absolute abundance
- LMIC-deployable qPCR derivative
- Public database and code release

### Subsequent Publications

1. FRESH application paper (main cohort findings)
2. South African reference database paper
3. HIV acquisition risk and functional genes
4. Model system validation of functional candidates

---

## Funding Strategy

### R21 (Exploratory/Developmental)
- $275K/year for 2 years
- Good fit for methods development
- Lower preliminary data requirements
- Leads to R01 for full application

### Alternative Mechanisms
- R01 (if strong preliminary data)
- U01 (consortium/cooperative agreement)
- Foundation grants (Gates, Wellcome)
- LMIC-focused mechanisms

---

## Key Innovation Points

1. **Species/strain resolution without metagenomics:** Multi-marker approach (cpn60 + rpoB + 16S) provides validated species-level taxonomy at amplicon costs

2. **Functional readouts from amplicons:** Direct quantification of inflammation-associated genes without expensive shotgun sequencing

3. **Absolute quantification:** UMI-tagged amplicons + spike-in normalization provides true molecule counts

4. **Multi-marker concordance:** Novel bioinformatics approach flags discordances, identifies database gaps, builds confidence

5. **Dual-use design:** Same primer binding sites enable both high-resource sequencing and LMIC qPCR deployment

6. **Population-specific reference:** South African database addresses bias in existing resources

---

## Outstanding Questions

1. Sequencing platform: iSeq for validation, NovaSeq for scale-up?
2. Mock community source: Zymo vaginal mock vs. custom from isolates?
3. Collaborator metagenomics for validation comparison?
4. R21 vs. alternative funding mechanism timing?
5. Isolate WGS timeline (informs database building)?

---

## Contacts and Resources

### Key Literature
- cpn60 vaginal: Hill lab publications (Links et al.)
- VOGUE reference: [cpnDB publications]
- rpoB for microbiome: BMC Microbiology 2019
- UMI amplicons: Nature Methods 2021

### Databases
- cpnDB: www.cpndb.ca
- VOGUE: Contact Hill lab
- SILVA: www.arb-silva.de
- GreenGenes2: greengenes2.ucsd.edu

### Tools
- DegePrime: Primer design for degenerate primers
- ARDEP: k-mer based primer design
- DADA2: ASV inference
- AmpUMI: UMI processing

---

*Document created: December 2025*
*Version: 1.0*
*Authors: Scott Handley, Claude Code collaboration*
</pre></div><button class="expand-btn">Show more</button></div>
</div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-17-14-418Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-17-14-418Z" class="timestamp-link"><time datetime="2025-12-14T23:17:14.418Z" data-timestamp="2025-12-14T23:17:14.418Z">2025-12-14T23:17:14.418Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>File created successfully at: /Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-17-827Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-17-827Z" class="timestamp-link"><time datetime="2025-12-14T23:17:17.827Z" data-timestamp="2025-12-14T23:17:17.827Z">2025-12-14T23:17:17.827Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Now let me search for funding opportunities:</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-18-120Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-18-120Z" class="timestamp-link"><time datetime="2025-12-14T23:17:18.120Z" data-timestamp="2025-12-14T23:17:18.120Z">2025-12-14T23:17:18.120Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01QanYPVHcayempqgGXkoAve"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;NIH R21 microbiome methods development 2025 funding opportunity&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-18-581Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-18-581Z" class="timestamp-link"><time datetime="2025-12-14T23:17:18.581Z" data-timestamp="2025-12-14T23:17:18.581Z">2025-12-14T23:17:18.581Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01ApUqpd7VxvJMXqRsRfGNEV"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;NIH NIAID HIV microbiome research funding 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-19-077Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-19-077Z" class="timestamp-link"><time datetime="2025-12-14T23:17:19.077Z" data-timestamp="2025-12-14T23:17:19.077Z">2025-12-14T23:17:19.077Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01SQJ6pBfxzWbqimDjeiH3SB"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;Gates Foundation microbiome diagnostics LMIC global health funding 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-17-42-642Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-17-42-642Z" class="timestamp-link"><time datetime="2025-12-14T23:17:42.642Z" data-timestamp="2025-12-14T23:17:42.642Z">2025-12-14T23:17:42.642Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;NIH NIAID HIV microbiome research funding 2025&quot;

Links: [{&quot;title&quot;:&quot;NIAID Microbiome Program | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/research/microbiome-program&quot;},{&quot;title&quot;:&quot;September 2025 DAIDS Council-Approved Concepts | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://pubweb-prod.niaid.nih.gov/grants-contracts/september-2025-daids-council-approved-concepts&quot;},{&quot;title&quot;:&quot;NIAID Funding News | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/funding-news&quot;},{&quot;title&quot;:&quot;Gastrointestinal Microbiology &amp; Infectious Diseases - NIDDK&quot;,&quot;url&quot;:&quot;https://www.niddk.nih.gov/research-funding/research-programs/gastrointestinal-microbiology-infectious-diseases&quot;},{&quot;title&quot;:&quot;NIAID FY 2025 narrative&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/sites/default/files/fy2025cj.pdf&quot;},{&quot;title&quot;:&quot;Small Business Research: Priority Funding Topics for 2025 | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/small-business-funding-topics-2025&quot;},{&quot;title&quot;:&quot;NIH: National Institute of Allergy and Infectious Diseases | Leading research to understand, treat, and prevent infectious, immunologic, and allergic diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/funding-news/2023-03-16&quot;},{&quot;title&quot;:&quot;Biomedical Research Funding: NIH Fiscal Year 2026 Recommendation&quot;,&quot;url&quot;:&quot;https://www.aai.org/AAISite/media/Public_Affairs/Position_Statements/AAI-Position-Statement-on-NIH-Funding.pdf&quot;},{&quot;title&quot;:&quot;NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/sites/default/files/niaid-fy26-cj.pdf&quot;},{&quot;title&quot;:&quot;Research Funded by NIAID | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/research/research-funded-niaid&quot;}]

Based on my search, here&#x27;s what I found about NIH NIAID HIV microbiome research funding for 2025:

## NIAID Microbiome Program

The NIAID Microbiome Program is a collaborative effort to explore the metaorganism using existing and new facilities and personnel. The program has developed a microbiome sequencing facility with bioinformatics support and a gnotobiotic mouse facility and is currently expanding microbiology resources. The program has supported over 35 groups across the National Institutes of Health (NIH) in their research related to the exploration of the metaorganism.

## NIAID FY 2025 Budget

With a FY 2025 budget of $6.562 billion, NIAID is the second largest NIH IC (behind NCI) and primary funder of foundational research on the development and function of the immune system. This work is critical to understanding chronic conditions like obesity, autoimmune diseases, cancer and neurodegeneration, as well as infectious diseases like influenza, measles, malaria, and HIV/AIDS.(no content)The FY 2025 President&#x27;s Budget request for NIAID was $6,581.3 million. NIAID will support a total of 5,450 Research Project Grant (RPG) awards in FY 2025.(no content)NIAID HIV/AIDS total funding is $1,911,364 thousand in FY 2025.

## HIV-Related Research Priorities

The Targeted Interventions Branch within NIAID&#x27;s Division of AIDS is interested in the discovery and development of small molecule inhibitors with novel mechanisms of action, cell-based and gene therapies, RNA-based therapeutics, next-generation biologics, novel targeting and delivery vehicles for agents active against HIV, therapeutic vaccines and monoclonal antibodies, and assays to quantitate latent virus.(no content)NIAID seeks to develop and advance approaches in genomic technologies, computational tools, and large-scale data analysis of human pathogens and their interactions with the host and microbiome.

## FY 2027 Upcoming HIV Initiatives

NIAID has council-approved concepts for FY 2027 including &quot;Implementation Science to Advance HIV Prevention, Treatment, and Care.&quot; The objective is to solicit implementation science to advance the goal of ending the HIV epidemic, requiring novel, locally tailored solutions as well as systematic development of generalized knowledge and scale-up of effective interventions.

## Note on FY 2026 Proposed Changes

The FY 2026 President&#x27;s Budget request for NIAID is $4,175.0 million, a decrease of $2,386.7 million or 36.4 percent compared to the FY 2025 Full-Year CR level. Overall percent reductions are distributed across all programmatic areas including basic, translational and clinical research.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-17-44-497Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-17-44-497Z" class="timestamp-link"><time datetime="2025-12-14T23:17:44.497Z" data-timestamp="2025-12-14T23:17:44.497Z">2025-12-14T23:17:44.497Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;NIH R21 microbiome methods development 2025 funding opportunity&quot;

Links: [{&quot;title&quot;:&quot;RFA-RM-08-009: Development of New tools for Computational Analysis of Human Microbiome Project Data (R21)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-009.html&quot;},{&quot;title&quot;:&quot;Expired RFA-RM-08-027: Development of New Technologies Needed for Studying the Human Microbiome (R21)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-027.html&quot;},{&quot;title&quot;:&quot;Microbiome Research | EGRP/DCCPS/NCI/NIH&quot;,&quot;url&quot;:&quot;https://epi.grants.cancer.gov/microbiome-research/&quot;},{&quot;title&quot;:&quot;PA-25-306: NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/pa-files/PA-25-306.html&quot;},{&quot;title&quot;:&quot;Microbiome Grants - USF Health - University of South Florida&quot;,&quot;url&quot;:&quot;https://health.usf.edu/medicine/microbiome/grants&quot;},{&quot;title&quot;:&quot;RFA-RM-08-010: Development of New Technologies Needed for Studying the Human Microbiome (R01)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-08-010.html&quot;},{&quot;title&quot;:&quot;Funding Opportunities | NIH Common Fund&quot;,&quot;url&quot;:&quot;https://commonfund.nih.gov/hmp/funding-opportunities&quot;},{&quot;title&quot;:&quot;PA-25-304: NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html&quot;},{&quot;title&quot;:&quot;Expired RFA-RM-09-008: Development of New Technologies Needed for Studying the Human Microbiome (R01)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-09-008.html&quot;},{&quot;title&quot;:&quot;Exploratory/Developmental Grants (R21) | Grants &amp; Funding&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/funding/activity-codes/r21&quot;}]

Based on my search, I found information about NIH R21 funding opportunities related to microbiome research and methods development. Here&#x27;s what I found:

## Current NIH R21 Funding Opportunities

### Parent R21 Announcements (2025)
The NIH Exploratory/Developmental Grant supports exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

Two current parent R21 announcements are available:
- **PA-25-304**: This Notice of Funding Opportunity does not accept applications proposing clinical trial(s).
- **PA-25-306**: This Parent Notice of Funding Opportunity requires that at least 1 clinical trial be proposed.(no content)These funding opportunities were updated on March 31, 2025 to align with agency priorities. Applicants should carefully reread the full funding opportunity and make any needed adjustments to their application prior to submission.

### Microbiome-Specific Opportunities

EGRP (NCI) encourages methods development or hypothesis-driven investigator-initiated grant applications on the topic of microbiome research.

Related active opportunities with microbiome relevance include:

1. **Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)** - Due dates include June 16, 2025, July 16, 2025, September 7, 2025, October 16, 2025, November 16, 2025.

2. Research interests include studies that examine the effects of prebiotics/probiotics and other natural products on gut microbiome-brain interactions, with particular interest in studies of prebiotics/probiotics for depression, anxiety disorders, irritable bowel syndrome (IBS), or chronic pain.

### Historical Human Microbiome Project FOAs (Now Expired)

The Human Microbiome Project has transitioned from Common Fund support. Since the Human Microbiome Project is no longer being supported by the Common Fund, the program website is being maintained as an archive and will not be updated on a regular basis.

Previous R21 FOAs included:
- Development of New Tools for Computational Analysis of Human Microbiome Project Data (R21) and Development of New Technologies Needed for Studying the Human Microbiome (R21).

### R21 General Information
The Research Strategy may not exceed 6 pages. Investigators are strongly encouraged to consult with NIH Scientific/Research staff during the concept development stage of the application to determine if an R21 application is appropriate.

I did not find a specific 2025 funding opportunity announcement explicitly titled for &quot;microbiome methods development.&quot; Researchers interested in this area would likely need to apply through the Parent R21 mechanism (PA-25-304 or PA-25-306) or contact NIH program staff to identify relevant Notices of Special Interest (NOSIs) that may apply to microbiome methods development.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-17-45-511Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-17-45-511Z" class="timestamp-link"><time datetime="2025-12-14T23:17:45.511Z" data-timestamp="2025-12-14T23:17:45.511Z">2025-12-14T23:17:45.511Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;Gates Foundation microbiome diagnostics LMIC global health funding 2025&quot;

Links: [{&quot;title&quot;:&quot;Research Technology Platforms | Global Grand Challenges&quot;,&quot;url&quot;:&quot;https://gcgh.grandchallenges.org/challenge/collaboratory-platforms-2023-democratizing-access-technologies&quot;},{&quot;title&quot;:&quot;Philanthropic Partnership Launches New Initiative Tackling Antimicrobial Resistance, the Third-Leading Cause of Death Globally, By Fast-Tracking Discovery of New Treatments&quot;,&quot;url&quot;:&quot;https://www.gatesfoundation.org/ideas/media-center/press-releases/2025/02/amr-bacteria-treatment-discovery&quot;},{&quot;title&quot;:&quot;Gates Foundation Committed Grants Database&quot;,&quot;url&quot;:&quot;https://www.gatesfoundation.org/about/committed-grants/2017/11/inv-009013&quot;},{&quot;title&quot;:&quot;SNIPR Biome Secures Gates Foundation Funding to Combat Environmental Enteric Dysfunction in Pregnant Women - SynBioBeta&quot;,&quot;url&quot;:&quot;https://www.synbiobeta.com/read/snipr-biome-secures-gates-foundation-funding-to-combat-environmental-enteric-dysfunction-in-pregnant-women&quot;},{&quot;title&quot;:&quot;Gates Foundation leads $50 million antimicrobial resistance initiative | Philanthropy news | PND&quot;,&quot;url&quot;:&quot;https://philanthropynewsdigest.org/news/gates-foundation-leads-50-million-antimicrobial-resistance-initiative&quot;},{&quot;title&quot;:&quot;Novo Nordisk Foundation, Wellcome, and the Gates Foundation Join Forces to Accelerate Global Health Equity and Impact - Microbiome Times Magazine&quot;,&quot;url&quot;:&quot;https://www.microbiometimes.com/novo-nordisk-foundation-wellcome-and-the-gates-foundation-join-forces-to-accelerate-global-health-equity-and-impact/&quot;},{&quot;title&quot;:&quot;Gatesfoundation&quot;,&quot;url&quot;:&quot;https://www.gatesfoundation.org/-/media/files/bmgf-grants.csv?rev=8be951d649634d1baff4f29707287786&amp;hash=8D6DF071AC491B7857EC0ECB8F139A47&quot;},{&quot;title&quot;:&quot;Global Health &amp; WASH: December 2025 Funding Opportunities (12 new opportunities!)&quot;,&quot;url&quot;:&quot;https://impactfunding.substack.com/p/global-health-and-wash-december-2025&quot;},{&quot;title&quot;:&quot;A $2.5 billion catalyst: how the Gates Foundation is redefining womenâ€™s health innovationâ€”with the microbiome in the spotlight - MicrobiomePost&quot;,&quot;url&quot;:&quot;https://microbiomepost.com/a-2-5-billion-catalyst-how-the-gates-foundation-is-redefining-womens-health-innovation-with-the-microbiome-in-the-spotlight/&quot;},{&quot;title&quot;:&quot;Homepage - The Gates Medical Research Institute&quot;,&quot;url&quot;:&quot;https://www.gatesmri.org/&quot;}]

Here are the search results for Gates Foundation microbiome diagnostics in LMICs and global health funding for 2025:

## Gates Foundation Microbiome &amp; Global Health Funding 2025

### Major Funding Initiatives

**$2.5 Billion Women&#x27;s Health Investment**
Among the five high-priority areas receiving catalytic funding is gynecological and menstrual health, with a strong emphasis on the vaginal microbiome. The new wave of investments will drive tools, diagnostics, and therapeutic strategies to better understand and modulate the vaginal microbiota, creating novel opportunities for biotech startups and research centers working at the intersection of microbiome science and women&#x27;s health.(no content)The Gates Foundation&#x27;s move could be a turning point for microbiome scienceâ€”pushing it from academic curiosity to frontline application in diagnostics and prevention, especially in resource-constrained settings.

**$300 Million Global Health R&amp;D Partnership (2024-2027)**
In February 2025, the Gates Foundation, Novo Nordisk Foundation, and Wellcome announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment focused on combatting antimicrobial resistance (AMR) caused by bacteria that are among the leading contributors to AMR-associated deaths.(no content)Gr-ADI is the first investment of the three-year, $300 million global health R&amp;D partnership announced in 2024, broadly focused on supporting science and innovation to advance solutions to health challenges that disproportionately impact people in low- and middle-income countries (LMIC).

### Microbiome-Specific Grants

**SNIPR Biome Funding**
SNIPR Biome received funding from the Gates Foundation to support the development of a microbiome-directed intervention aimed at improving environmental enteric dysfunction (EED) by reducing gut entero-pathogen burden in pregnant women from low- and middle-income countries (LMICs).(no content)The grant aims to generate CRISPR-armed phages (CAPs) from SNIPR Biome&#x27;s extensive phage library, which possesses broad and robust antibacterial activity against Escherichia coli and Klebsiella pneumoniae strains sourced from LMIC sites.

### Current Funding Opportunities (December 2025)

The Gates Foundation&#x27;s Grand Challenges platform has an open call for innovative proposals to develop vaginal formulations that deliver therapeutic or preventive agents while supporting vaginal health. Grants are available for projects that explore scalable, low-cost solutions tailored to LMIC contexts, including proposals focused on enhancing the vaginal microbiome.(no content)Eligibility includes legally registered institutions such as nonprofits, academic centers, companies, or research groups, with emphasis on LMIC- and women-led teams. Grants range from USD $100,000 - $250,000 per project.

### LMIC Collaboratory Platforms Program

The Global Health Discovery Collaboratory (GHDC) Platforms program at the Bill &amp; Melinda Gates Foundation lowers barriers to accessing best-in-class tools, cross-cutting technology platforms, and expertise for grantee members to accelerate discovery and translation of transformative solutions to global health inequity.(no content)This includes vaginal microbiome innovations to enable discovery of probiotic formulations and improved understanding of longitudinal microbiome dynamics before, during and after pregnancy, with funding up to USD $250,000 per award for terms of up to two years.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-49-021Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-49-021Z" class="timestamp-link"><time datetime="2025-12-14T23:17:49.021Z" data-timestamp="2025-12-14T23:17:49.021Z">2025-12-14T23:17:49.021Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01PU3xzen3pcwEgrhV7jH9yM"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;NIH R03 R21 technology development infectious disease diagnostics 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-49-361Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-49-361Z" class="timestamp-link"><time datetime="2025-12-14T23:17:49.361Z" data-timestamp="2025-12-14T23:17:49.361Z">2025-12-14T23:17:49.361Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01UnvHkgAK58RtRDCJRRFBmC"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;Wellcome Trust global health diagnostics microbiome funding 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-17-50-028Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-17-50-028Z" class="timestamp-link"><time datetime="2025-12-14T23:17:50.028Z" data-timestamp="2025-12-14T23:17:50.028Z">2025-12-14T23:17:50.028Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01Wm6TaEa7wJMGSD4twtVPdQ"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;Fogarty International Center NIH global health research LMIC 2025 funding&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-18-10-031Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-18-10-031Z" class="timestamp-link"><time datetime="2025-12-14T23:18:10.031Z" data-timestamp="2025-12-14T23:18:10.031Z">2025-12-14T23:18:10.031Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;Fogarty International Center NIH global health research LMIC 2025 funding&quot;

Links: [{&quot;title&quot;:&quot;Funding news for global health researchers: April 7, 2025 - Fogarty International Center @ NIH&quot;,&quot;url&quot;:&quot;https://www.fic.nih.gov/Funding/News/Pages/global-health-funding-news-2025-04-07.aspx&quot;},{&quot;title&quot;:&quot;Fogarty International Center (FIC) | National Institutes of Health (NIH)&quot;,&quot;url&quot;:&quot;https://www.nih.gov/about-nih/nih-almanac/fogarty-international-center-fic&quot;},{&quot;title&quot;:&quot;Funding Collaborations - Fogarty International Center @ NIH&quot;,&quot;url&quot;:&quot;https://www.fic.nih.gov/Funding/Pages/Collaborations.aspx&quot;},{&quot;title&quot;:&quot;Fogarty Funding Concepts - Fogarty International Center @ NIH&quot;,&quot;url&quot;:&quot;https://www.fic.nih.gov/About/Advisory/Pages/funding-concepts.aspx&quot;},{&quot;title&quot;:&quot;Fogarty Extramural Programs - Fogarty International Center @ NIH&quot;,&quot;url&quot;:&quot;https://www.fic.nih.gov/Programs&quot;},{&quot;title&quot;:&quot;NIH Funding Opportunities â€“ H3Africa&quot;,&quot;url&quot;:&quot;https://h3africa.org/index.php/resource/funding/nih-funding-opportunities/&quot;},{&quot;title&quot;:&quot;New Apply | Global Health Fellows&quot;,&quot;url&quot;:&quot;https://fogartyfellows.org/apply/&quot;},{&quot;title&quot;:&quot;Fogarty International Center&quot;,&quot;url&quot;:&quot;https://www.fic.nih.gov/&quot;}]

Based on the search results, here&#x27;s information about the Fogarty International Center (FIC) at NIH and their global health research funding opportunities for LMICs in 2025:

## Fogarty International Center Overview

Fogarty collaborates with components of the National Institutes of Health and other partners to foster global health research on a variety of research and training opportunities involving low- and middle-income countries (LMICs).(no content)Fogarty&#x27;s extramural programs provide funding to perform research and to train researchers in a variety of global health areas. See program pages for status, eligibility, funding announcements and deadlines.

## 2025 Funding Opportunities

Key upcoming deadlines include:
- **HIV-associated Noncommunicable Diseases Research at LMIC Institutions** - Application deadline: December 8, 2025
- **Stigma HIV/AIDS** - Application deadline: December 22, 2025(no content)Fogarty is also a partner on Dissemination and Implementation Research in Health opportunities (PAR-25-233 and PAR-25-143) with multiple application due dates.

## Key LMIC-Focused Programs

The program &quot;Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries&quot; seeks to develop and test interventions to reduce the impact of HIV-associated stigma. The &quot;HIV-associated Noncommunicable Diseases Research at Low- and Middle-Income Country Institutions&quot; aims to build a network of researchers both within and across LMICs.(no content)Fogarty&#x27;s NCD research program aims to sustainably strengthen the NCD research capacity of LMIC institution(s), and to train in-country experts to develop and conduct research on NCDs across the lifespan. LMICs are defined by the World Bank Classification system as low, lower-middle, and upper-middle income countries.(no content)Globally, non-communicable diseases kill more than 41 million people each year with approximately 75% of these deaths occurring in LMICs.

## Recent Leadership Update

On April 11, 2025, NIH named Dr. Peter Kilmarx as the acting director of the Fogarty International Center.(no content)NIH is seeking applications from exceptional candidates for the position of Director, Fogarty International Center.

## Global Impact

When teams of U.S. and international scientists conduct research in low- and middle-income countries, it often leads to improved treatments for health challenges of importance to Americans, such as cancer, heart disease and child nutrition.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-18-12-433Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-18-12-433Z" class="timestamp-link"><time datetime="2025-12-14T23:18:12.433Z" data-timestamp="2025-12-14T23:18:12.433Z">2025-12-14T23:18:12.433Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;Wellcome Trust global health diagnostics microbiome funding 2025&quot;

Links: [{&quot;title&quot;:&quot;FORM | Wellcome Leap: Unconventional Projects. Funded at Scale.&quot;,&quot;url&quot;:&quot;https://wellcomeleap.org/form/&quot;},{&quot;title&quot;:&quot;Engineering the microbiome to expose the functional biogeography of the gut&quot;,&quot;url&quot;:&quot;https://wellcome.org/grant-funding/people-and-projects/grants-awarded/engineering-microbiome-expose-functional-biogeography&quot;},{&quot;title&quot;:&quot;Wellcome Leap | Major initiatives | Wellcome&quot;,&quot;url&quot;:&quot;https://wellcome.org/research-funding/funding-portfolio/major-initiatives/wellcome-leap&quot;},{&quot;title&quot;:&quot;Wellcome Trust - Wikipedia&quot;,&quot;url&quot;:&quot;https://en.wikipedia.org/wiki/Wellcome_Trust&quot;},{&quot;title&quot;:&quot;In new strategy, Wellcome Trust will take on global health challenges | Science | AAAS&quot;,&quot;url&quot;:&quot;https://www.science.org/content/article/new-strategy-wellcome-trust-will-take-global-health-challenges&quot;},{&quot;title&quot;:&quot;The top grantees of Wellcome | Devex&quot;,&quot;url&quot;:&quot;https://www.devex.com/news/the-top-grantees-of-wellcome-110886&quot;},{&quot;title&quot;:&quot;New Wellcome Trust funding for Imperial Life Sciences and Medicine research | Imperial News | Imperial College London&quot;,&quot;url&quot;:&quot;https://www.imperial.ac.uk/news/articles/medicine/2025/new-wellcome-trust-funding-for-imperial-life-sciences-and-medicine-research/&quot;},{&quot;title&quot;:&quot;Home | Wellcome Leap: Unconventional Projects. Funded at Scale.&quot;,&quot;url&quot;:&quot;https://wellcomeleap.org/&quot;},{&quot;title&quot;:&quot;The Wellcome Trust: new funding for mental health science - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC10168141/&quot;},{&quot;title&quot;:&quot;Microbiotica, the latest spin-out from the Wellcome Trust Sanger Institute | Cambridge Immunology Network&quot;,&quot;url&quot;:&quot;https://www.immunology.cam.ac.uk/news/microbiotica&quot;}]

Based on my search, here&#x27;s what I found about Wellcome Trust global health diagnostics, microbiome, and funding in 2025:

## Key Findings

### Wellcome Leap&#x27;s FORM Program (2025)
Wellcome Leap has launched a new $50M program called &quot;Foundations of a Resilient Microbiome&quot; (FORM).(no content)The program announcement was updated on November 14, 2025. The program aims to develop and validate screening methods, diagnostic biomarkers, and restoration strategies related to the human gut microbiome.(no content)The program includes developing scalable methods to objectively assess the functional contribution of the maternal and infant gut microbiome to infant neurodevelopment. This includes screening tools to predict risk of cognitive, language, social, and executive function challenges with &gt;70% accuracy, and diagnostic methods capable of identifying gut microbiome-based functional disorders with &gt;90% accuracy.

### Wellcome Trust Overall Funding Strategy
Over the past 10 years, Wellcome has provided Â£11.8 billion in grants to various health initiatives worldwide. In its 2022 strategy, Wellcome announced it would allocate Â£16 billion toward various research activities addressing urgent health matters until 2032.

### Global Health &amp; Diagnostics Partnerships
In 2015, the Wellcome Trust joined the Japanese government, 7 Japanese pharmaceutical and diagnostics companies, The Bill and Melinda Gates Foundation, and the United Nations Development Program as funding partner of the Global Health Innovative Technology Fund (GHIT), which funds scientific research and development for anti-infectives and diagnostics for diseases that primarily affect the developing world.

### Recent Microbiome Research Funding
A team of Imperial scientists received approximately Â£2.7 million through the Wellcome Trust Discovery Award. The research focuses on capsid-forming phage-inducible chromosomal islands (cf-PICIs), a recently discovered mechanism by which bacteria exchange DNA across species.(no content)This approach has the potential to develop new therapeutics that selectively kill harmful pathogens or edit bacteria within a complex microbiota. The team hopes their research will advance understanding of bacterial evolution and pave the way for innovative therapeutic approaches to tackle multidrug-resistant infections.

### Mental Health and Microbiome Research
Wellcome is also funding Prof. L. Kenny from the University of Liverpool to supplement a new cohort to collect microbiome data at birth in the UK, with follow-up to assess impacts on anxiety and depression at later stages.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-18-14-360Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-18-14-360Z" class="timestamp-link"><time datetime="2025-12-14T23:18:14.360Z" data-timestamp="2025-12-14T23:18:14.360Z">2025-12-14T23:18:14.360Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;NIH R03 R21 technology development infectious disease diagnostics 2025&quot;

Links: [{&quot;title&quot;:&quot;NIGMS Technology Development Programs (R21 and R01) | National Institute of General Medical Sciences&quot;,&quot;url&quot;:&quot;https://www.nigms.nih.gov/grants/R21-R01/Pages/NIGMS-Technology-Development-Programs-R21-and-R01&quot;},{&quot;title&quot;:&quot;PAR-25-202: Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html&quot;},{&quot;title&quot;:&quot;Trans-NIAID Data Science Program | NIH: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/research/trans-niaid-data-science-program&quot;},{&quot;title&quot;:&quot;IDM (12) | NIH Center for Scientific Review&quot;,&quot;url&quot;:&quot;https://public.csr.nih.gov/StudySections/DPPS/IDM/IDM12&quot;},{&quot;title&quot;:&quot;News Briefs and Worth Repeating | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/news-briefs-and-worth-repeating-june-5&quot;},{&quot;title&quot;:&quot;NIH Proposal Checklistâ€”R01/R03/R21 Clinical Trial Not Required Jan 2025&quot;,&quot;url&quot;:&quot;https://www.marquette.edu/research-sponsored-programs/documents/nih_r01-r03-r21_no-ct_jan2025.pdf&quot;},{&quot;title&quot;:&quot;NIAID Updates Interim R01, R03, and R21 Paylines | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/niaid-updates-interim-r01-r03-and-r21-paylines&quot;},{&quot;title&quot;:&quot;Sample Applications &amp; More | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/grants-contracts/sample-applications&quot;},{&quot;title&quot;:&quot;PAR-25-203: Focused Technology Research and Development (R01 Clinical Trial Not Allowed)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/pa-files/PAR-25-203.html&quot;},{&quot;title&quot;:&quot;Frequently Asked Questions About NIGMS Technology Development Notices of Funding Opportunities | National Institute of General Medical Sciences&quot;,&quot;url&quot;:&quot;https://www.nigms.nih.gov/grants/R21-R01/Pages/FAQs-About-NIGMS-Technology-Development-FOAs&quot;}]

Based on my search, here&#x27;s what I found about NIH R03, R21, and technology development for infectious disease diagnostics in 2025:

## NIH Technology Development Programs

### NIGMS Technology Development R21 and R01
The NIGMS Technology Development R21 and R01 notice of funding opportunities (NOFOs) support technological innovations to advance biomedical research.

**PAR-25-202 (R21):** This Notice of Funding Opportunity (NOFO) supports exploratory research leading to proof of concept for the development of new technologies relevant to the NIGMS mission. Projects should entail a high degree of risk and/or novelty, and have a high future potential impact in biomedical research.

**PAR-25-203 (R01):** This NOFO invites research applications with a focus on early stage technology development and validation before the technologies are ready for application to untested biological questions and wide dissemination. Early technology development can be described in two stages: (I) exploratory proof-of-concept research to determine feasibility and best approach(es) for a technology development project, and (II) subsequent research and development that focuses exclusively on creating and validating a working prototype technology. This NOFO invites projects in Stage II.(no content)March 31, 2025 - This funding opportunity was updated to align with agency priorities.

### Infectious Disease Diagnostics Review Panel (IDM-12)
IDM (12) reviews Small Business Innovation Research [SBIR], Small Business Technology Transfer Research [STTR] and R03 and R21 grant applications that focus on the development of (non-HIV) microbial detection, quantitation, and diagnostics; detection of food and waterborne pathogens, and development of technologies to advance areas of microbial sterilization, disinfection, and bioremediation.(no content)The panel considers grant applications that deal with detection and diagnostics of bacteria, non-HIV viruses, eukaryotic pathogens, parasites, and prions.

### Key Grant Characteristics

**R03 (Small Grants):** The small grant (R03) supports new research projects that can be carried out in a short period of time with limited resources. They are awarded for up to 2 years and are not renewable.

**R21 (Exploratory/Developmental):** The R21 funds novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research. R21s are not intended for new investigators, and there is no evidence that they provide a path to an independent research career.

### Important R21 Requirements for NIGMS Tech Development
The R21 supports novel concepts that have not yet been tested for feasibility. Thus, unpublished or any data that support feasibility or proof of concept are not allowed. Because proof of concept must not already be developed, NIGMS expects the projects to be high-risk.(no content)For technology development R21, applications with preliminary data that support proof-of-concept or feasibility will be considered non-responsive and withdrawn without review.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-18-18-034Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-18-18-034Z" class="timestamp-link"><time datetime="2025-12-14T23:18:18.034Z" data-timestamp="2025-12-14T23:18:18.034Z">2025-12-14T23:18:18.034Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01CQN1w3rxRmkZpMMKUgjAsa"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;NIH NOSI notice special interest HIV prevention microbiome women 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-18-18-330Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-18-18-330Z" class="timestamp-link"><time datetime="2025-12-14T23:18:18.330Z" data-timestamp="2025-12-14T23:18:18.330Z">2025-12-14T23:18:18.330Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_01Ach8AorgxSbBq25KpV3Mko"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;NIH administrative supplement microbiome methods technology 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-18-38-143Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-18-38-143Z" class="timestamp-link"><time datetime="2025-12-14T23:18:38.143Z" data-timestamp="2025-12-14T23:18:38.143Z">2025-12-14T23:18:38.143Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;NIH administrative supplement microbiome methods technology 2025&quot;

Links: [{&quot;title&quot;:&quot;Expired PA-18-876: Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01 Clinical Trial Not Allowed)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/pa-files/PA-18-876.html&quot;},{&quot;title&quot;:&quot;Microbiome Research | EGRP/DCCPS/NCI/NIH&quot;,&quot;url&quot;:&quot;https://epi.grants.cancer.gov/microbiome-research/&quot;},{&quot;title&quot;:&quot;Therapeutic engineering of the gut microbiome using synthetic biology and metabolic tools: a comprehensive review with E. coli Nissle 1917 as a model case study - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC12328466/&quot;},{&quot;title&quot;:&quot;Gastrointestinal Microbiology &amp; Infectious Diseases - NIDDK&quot;,&quot;url&quot;:&quot;https://www.niddk.nih.gov/research-funding/research-programs/gastrointestinal-microbiology-infectious-diseases&quot;},{&quot;title&quot;:&quot;Precision Microbiome: A New Era of Targeted Therapy with Core Probiotics - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC11938712/&quot;},{&quot;title&quot;:&quot;The role of Micro-biome engineering in enhancing Food safety and quality - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/39912062/&quot;},{&quot;title&quot;:&quot;NIAID Microbiome Program | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/research/microbiome-program&quot;},{&quot;title&quot;:&quot;Administrative Supplements | Grants &amp; Funding&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/funding/funding-categories/supplemental-funding/administrative-supplements&quot;},{&quot;title&quot;:&quot;NIGMS Priority Areas for Administrative Supplements - NIH&quot;,&quot;url&quot;:&quot;https://nigms.nih.gov/loop/2025/03/nigms-priority-areas-for-administrative-supplements&quot;},{&quot;title&quot;:&quot;Human Microbiome Project (HMP) | NIH Common Fund&quot;,&quot;url&quot;:&quot;https://commonfund.nih.gov/hmp&quot;}]

Based on my search, here&#x27;s what I found regarding NIH administrative supplements related to microbiome methods and technology:

## NIH Administrative Supplements Overview

Administrative supplements may be used to support a variety of unanticipated circumstances, including full or part-time mentored research training experiences for individuals with high potential to reenter, reintegrate into, or retrain in an active research career, retention of investigators facing critical life events, and salary and training expenses to augment clinical research studies with unexpected necessary expertise.(no content)Administrative supplements can also support the application of a new technology (e.g., changing assays, equipment) for peer-reviewed studies, third-party replication of research findings within the parent award, and data preparation and curation to make data Findable, Accessible, Interoperable, and Reusable (FAIR).

## NIGMS 2025 Administrative Supplements

For consideration in FY25, applicants are encouraged to submit supplement requests by April 18, 2025 (previously March 31, 2025). NIGMS strongly advises grantees to contact their program officers prior to submitting applications for administrative supplements to assure that their awards are eligible and that the application meets the requirements.

## Microbiome Research at NIH

EGRP (Epidemiology and Genomics Research Program) encourages methods development or hypothesis-driven investigator-initiated grant applications on the topic of microbiome research.(no content)The NIAID Microbiome Program is a collaborative effort to explore the metaorganism using existing and new facilities and personnel. The program has developed a microbiome sequencing facility with bioinformatics support and a gnotobiotic mouse facility and is currently expanding microbiology resources. The program has supported over 35 groups across the NIH in their research related to the exploration of the metaorganism.(no content)The Common Fund&#x27;s Human Microbiome Project (HMP) developed research resources to enable the study of the microbial communities that live in and on our bodies and the roles they play in human health and disease. The HMP was established with the mission of generating research resources, which were rapidly and broadly shared, enabling comprehensive characterization of the human microbiota and their metabolic capabilities.

I didn&#x27;t find a specific 2025 administrative supplement announcement focused specifically on &quot;microbiome methods technology.&quot; However, general administrative supplement mechanisms exist that could support microbiome-related technology development. Would you like me to search for more specific funding opportunities or recent announcements?


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-18-49-228Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-18-49-228Z" class="timestamp-link"><time datetime="2025-12-14T23:18:49.228Z" data-timestamp="2025-12-14T23:18:49.228Z">2025-12-14T23:18:49.228Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;NIH NOSI notice special interest HIV prevention microbiome women 2025&quot;

Links: [{&quot;title&quot;:&quot;Expired NOT-AI-23-070: Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/not-ai-23-070.html&quot;},{&quot;title&quot;:&quot;Expired NOT-OD-24-079: Notice of Special Interest: Womens Health Research&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-079.html&quot;},{&quot;title&quot;:&quot;NOT-HL-23-089: Notice of Special Interest (NOSI): Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-HL-23-089.html&quot;},{&quot;title&quot;:&quot;Expired NOT-AI-24-059: Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-059.html&quot;},{&quot;title&quot;:&quot;Notice of Special Interest (NOSI) SOP | NIAID: National Institute of Allergy and Infectious Diseases&quot;,&quot;url&quot;:&quot;https://www.niaid.nih.gov/research/notice-special-interest-nosi-sop&quot;},{&quot;title&quot;:&quot;NOT-HL-22-010: Notice of Special Interest (NOSI): Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-HL-22-010.html&quot;},{&quot;title&quot;:&quot;Expired NOT-MH-23-200: Notice of Special Interest (NOSI): Innovative Technologies to develop novel tools to prevent and treat HIV in underserved populations&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-MH-23-200.html&quot;},{&quot;title&quot;:&quot;Expired NOT-AI-24-031: Notice of Special Interest (NOSI): Resource-Related Research Project (R24) Applications to Support Collaborative Implementation Science to End the HIV Epidemic&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-031.html&quot;},{&quot;title&quot;:&quot;Expired NOT-OD-24-146: Notice of Special Interest (NOSI): Improving Adherence to Treatment and Prevention Regimens and Maintenance of Health Behaviors to Promote Health&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-146.html&quot;},{&quot;title&quot;:&quot;NOT-MD-21-020: Notice of Special Interest (NOSI): Administrative Supplements to NIMHD Awards for Research on HIV/AIDS in Populations that Experience Health Disparities (Admin Supp Clinical Trial Optional)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-MD-21-020.html&quot;}]

Based on the search results, I found several NIH Notices of Special Interest (NOSIs) related to HIV research, but I didn&#x27;t find a specific NOSI about HIV prevention, microbiome, and women for 2025. Let me search more specifically:

Links: [{&quot;title&quot;:&quot;Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/34120819/&quot;},{&quot;title&quot;:&quot;The microbiome and HIV prevention strategies in women - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/29059077/&quot;},{&quot;title&quot;:&quot;The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/31144462/&quot;},{&quot;title&quot;:&quot;Optimizing the vaginal microbiome as a potential strategy to reduce heterosexual HIV transmission - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/36544257/&quot;},{&quot;title&quot;:&quot;The Vaginal Microbiome and Its Potential to Impact Efficacy of HIV Pre-Exposure Prophylaxis for Women - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC5693614/&quot;},{&quot;title&quot;:&quot;Effect of initiation of antiretroviral drugs for HIV prevention or treatment on the vaginal microbiome of pregnant women in Malawi - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/40287413/&quot;},{&quot;title&quot;:&quot;Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561602/&quot;},{&quot;title&quot;:&quot;Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention - PubMed&quot;,&quot;url&quot;:&quot;https://pubmed.ncbi.nlm.nih.gov/28818087/&quot;},{&quot;title&quot;:&quot;The Vaginal Microbiome and HIV Transmission Dynamics - PMC&quot;,&quot;url&quot;:&quot;https://pmc.ncbi.nlm.nih.gov/articles/PMC11756713/&quot;},{&quot;title&quot;:&quot;The genital tract and rectal microbiomes: their role in HIV susceptibility and prevention in women - PMC&quot;,&quot;url&quot;:&quot;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6541743/&quot;}]

The search returned many research articles about the vaginal microbiome and HIV prevention in women, but I didn&#x27;t find a specific NIH NOSI notice. Let me search more directly for this specific funding announcement:

Links: [{&quot;title&quot;:&quot;NOT-AI-23-046: Notice of Special Interest (NOSI): HIV Cure-Related Research in Diverse Populations&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-046.html?amp=&amp;amp=&amp;amp=&amp;amp=&quot;},{&quot;title&quot;:&quot;NOT-AI-25-001: Notice of Early Expiration of \&quot;Notice of Special Interest (NOSI): Leveraging Microbial Exposure for Improving Mouse Models of Human Immunity\&quot;, NOT-AI-21-072&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-25-001.html&quot;},{&quot;title&quot;:&quot;NOT-AI-21-057: Notice of Special Interest (NOSI) HIV/AIDS in the Era of COVID-19: When Pandemics Collide&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-21-057.html?amp=&amp;amp=&amp;amp=&amp;amp=&quot;},{&quot;title&quot;:&quot;NOT-AI-22-056: Notice of Special Interest (NOSI): Opportunities for HIV Cure Interventions at the Time of ART Initiation&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-22-056.html&quot;},{&quot;title&quot;:&quot;NIH Funding Opportunities and Notices for The Week Ending08-26-2022&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/WeeklyIndexMobile.cfm?WeekEnding=08-26-2022&quot;},{&quot;title&quot;:&quot;Expired NOT-AI-23-070: Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-070.html&quot;},{&quot;title&quot;:&quot;Expired NOT-AI-24-059: Notice of Special Interest (NOSI): Ending the HIV Epidemic (EHE)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-24-059.html&quot;},{&quot;title&quot;:&quot;Expired RFA-HD-23-026: NICHD Program Project Grants for HIV Research (P01 Clinical Trial Optional)&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-23-026.html&quot;},{&quot;title&quot;:&quot;NOT-AI-23-045: Notice of Special Interest (NOSI): Understanding Mucosal Immunity Against Enteric Eukaryotic Pathogens to Advance Discovery of New Interventions&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/NOT-AI-23-045.html&quot;},{&quot;title&quot;:&quot;NOT-AI-21-032: Notice of Special Interest (NOSI): Investigations on Inborn Errors of Immunity/Primary Immunodeficiencies&quot;,&quot;url&quot;:&quot;https://grants.nih.gov/grants/guide/notice-files/not-ai-21-032.html&quot;}]

Based on my searches, I was unable to find a specific NIH NOSI notice that specifically addresses HIV prevention, microbiome, and women for 2025 with that exact combination of terms. However, I found several related NIH funding opportunities and research information:

## Related NIH Notices of Special Interest (NOSI) and Funding Opportunities Found:

### HIV-Related NOSIs:
1. **NOT-AI-23-070 (Expired)** and **NOT-AI-24-059 (Expired)**: Ending the HIV Epidemic (EHE) initiatives - These NOSIs solicit applications proposing research grounded in implementation science to address the goals of the EHE initiative, with goals of reducing HIV infections by 75% by 2025 and 90% by 2030.

2. **NOT-HL-23-089**: Research on barriers to care and risk of HIV-associated comorbidities among vulnerable population groups - This supports analysis of barriers to care and risk of HIV-associated comorbidities among disproportionally vulnerable and affected population groups.(no content)This notice applied through May 7, 2025, with no applications accepted on or after May 8, 2025.

3. **NOT-OD-24-079 (Expired)**: Women&#x27;s Health Research - This NOSI highlighted interest in research on diseases that predominantly affect women, present differently in women (including HIV), or are female-specific.

### Research on Microbiome and HIV Prevention in Women:
While I didn&#x27;t find a specific NOSI with all these terms, there is significant published research on this topic:

- Research indicates that given the important role of the vaginal microbiome in determining HIV susceptibility, altering the microbiome towards a Lactobacillus-dominated state is an attractive complementary strategy to reduce HIV incidence rates.

- Findings that the female genital microbiome can influence HIV acquisition and prevention emphasize the importance of microbiome analysis in clinical trials that assess the efficacy of HIV prevention interventions.

- The NICHD Program Project Grants for HIV Research (RFA-HD-23-026) included research on immune status and inflammation in HIV exposure or infection, including gut microbiome/virome changes.

If you&#x27;re looking for a specific NOSI related to HIV prevention, microbiome, and women&#x27;s health for 2025, I recommend checking the NIH Guide directly at grants.nih.gov or contacting NIAID program staff, as there may be newer or more specific announcements that weren&#x27;t captured in these search results.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-18-52-683Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-18-52-683Z" class="timestamp-link"><time datetime="2025-12-14T23:18:52.683Z" data-timestamp="2025-12-14T23:18:52.683Z">2025-12-14T23:18:52.683Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_014yDWnof2qmifQDAXoGK5vp"><div class="tool-header"><span class="tool-icon">âš™</span> WebSearch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;query&#34;: &#34;\&#34;Grand Challenges\&#34; vaginal microbiome HIV women global health 2025&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-18-53-875Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-18-53-875Z" class="timestamp-link"><time datetime="2025-12-14T23:18:53.875Z" data-timestamp="2025-12-14T23:18:53.875Z">2025-12-14T23:18:53.875Z</time></a></div><div class="message-content">
<div class="tool-use" data-tool-id="toolu_018or9bsbeYocgcDxvoD4bHw"><div class="tool-header"><span class="tool-icon">âš™</span> WebFetch</div><div class="truncatable"><div class="truncatable-content"><pre class="json">{
  &#34;url&#34;: &#34;https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html&#34;,
  &#34;prompt&#34;: &#34;What are the details of this R21 technology development grant? What are the eligibility requirements, budget, and scope? What types of projects are supported?&#34;
}</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-19-00-081Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-19-00-081Z" class="timestamp-link"><time datetime="2025-12-14T23:19:00.081Z" data-timestamp="2025-12-14T23:19:00.081Z">2025-12-14T23:19:00.081Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre># PAR-25-202: Technology Development R21 Grant Details

## Overview
This NIH funding opportunity supports exploratory research to establish feasibility and proof of concept for new biomedical technologies at an early conceptual stage, before prototype development.

## Eligibility
- **Applicants**: Universities, nonprofits, for-profit organizations, government entities, and tribal organizations (U.S.-based only)
- **PD/PI**: Individuals with skills and resources to conduct the research
- **Application Types**: New applications only
- **Clinical Trials**: Not allowed

## Budget &amp; Duration
- **Maximum**: $275,000 direct costs over 2 years
- **Annual Cap**: $200,000 direct costs per year
- **Project Period**: 2 years maximum

## Supported Technologies
&quot;laboratory instruments and other devices, algorithms and software, chemical reagents and processes, biological molecules or systems that have been modified by human intervention for use as research tools.&quot;

## Key Scope Limitations

**What IS Supported:**
- Proof-of-concept studies for unproven technologies
- High-risk exploratory research
- Validation against well-characterized systems

**What IS NOT Supported:**
- Applications addressing specific biological questions
- Projects with existing published/unpublished proof-of-concept data
- Re-purposing existing technologies for new applications
- Incremental technology advances

## Important Requirement
Applications must include a signed letter from the PD/PI confirming adherence to responsiveness criteria. Omitting this letter results in administrative withdrawal without review.

**Next Deadline**: February 16, 2025 (first of multiple annual cycles)</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-19-11-713Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-19-11-713Z" class="timestamp-link"><time datetime="2025-12-14T23:19:11.713Z" data-timestamp="2025-12-14T23:19:11.713Z">2025-12-14T23:19:11.713Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>Web search results for query: &quot;&quot;Grand Challenges&quot; vaginal microbiome HIV women global health 2025&quot;

Links: [{&quot;title&quot;:&quot;Jo-Ann Passmore | Global Grand Challenges&quot;,&quot;url&quot;:&quot;https://gcgh.grandchallenges.org/champion/jo-ann-passmore&quot;},{&quot;title&quot;:&quot;Innovation in Vaginal Formulations in Womenâ€™s Health&quot;,&quot;url&quot;:&quot;https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-0&quot;},{&quot;title&quot;:&quot;Accelerating Innovation in Vaginal Formulations to Support Womenâ€™s Health. | Research and Innovation Directorate&quot;,&quot;url&quot;:&quot;https://rid.ug.edu.gh/node/440&quot;},{&quot;title&quot;:&quot;Request for Proposals (RFP): Accelerating Innovation in Vaginal Formulations in Support of Womenâ€™s Health - Apply Before 16 December 2025 - Global South Opportunities&quot;,&quot;url&quot;:&quot;https://www.globalsouthopportunities.com/2025/12/02/proposals/&quot;},{&quot;title&quot;:&quot;Accelerating Innovation in Vaginal Formulations: A Global Call to Advance Womenâ€™s Health - Opportunities for Youth&quot;,&quot;url&quot;:&quot;https://opportunitiesforyouth.org/2025/11/06/accelerating-innovation-in-vaginal-formulations-a-global-call-to-advance-womens-health/&quot;}]

Based on the search results, here&#x27;s what I found about &quot;Grand Challenges&quot; initiatives related to the vaginal microbiome, HIV, women&#x27;s health, and global health in 2025:

## Key Findings

### Grand Challenges Initiative on Vaginal Formulations for Women&#x27;s Health

The Science for Africa Foundation (SFA), in partnership with Grand Challenges and related country platforms, has launched an ambitious global initiative â€” &quot;Accelerating Innovation in Vaginal Formulations in Support of Women&#x27;s Health.&quot;(no content)The call for proposals aims to support the creation of next-generation vaginal formulations that not only deliver drugs effectively but also enhance user comfort and maintain vaginal health. Researchers, innovators, and organizations from across the world are invited to submit proposals by December 16, 2025.

### Program Focus Areas

Vaginal formulations hold significant promise for the management of reproductive tract infections (RTIs), sexually transmitted infections (STIs), contraceptive innovation, and maintenance of a healthy vaginal microbiome.(no content)While there has been meaningful progress in delivery systems such as gels, films, and intravaginal rings, major gaps remain in acceptability, scalability, affordability, and integration into routine care in LMICs.

### Research on HIV and the Vaginal Microbiome

Research by Jo-Ann Passmore, a Grand Challenges Champion, has found that genital inflammation increases the risk for women of becoming infected with HIV, and that this genital inflammation also reduces the efficacy of key HIV prevention tools. She has shown that bacterial vaginosis (BV), a common condition caused by an imbalance of naturally occurring bacteria in the vagina, is a major cause of genital inflammation.(no content)Building on her research, Jo-Ann is leading a major collaboration between African scientists to study the vaginal microbiomes of women in Africa.(no content)The initiative aims to leverage Pan-African research expertise to understand BV in Africa, and use this information to develop inexpensive, accessible tools to treat BV for women living in Africa.

### Implementation Partners

The initiative is implemented by Science for Africa Foundation (SFA Foundation) in partnership with the Bill &amp; Melinda Gates Foundation and the Global Grand Challenges network.(no content)Applicants must carefully review which Grand Challenges portal applies to their geographic location: South Africa uses the Grand Challenges South Africa portal, while other African countries use the Grand Challenges Africa portal.


REMINDER: You MUST include the sources above in your response to the user using markdown hyperlinks.</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-19-14-802Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-19-14-802Z" class="timestamp-link"><time datetime="2025-12-14T23:19:14.802Z" data-timestamp="2025-12-14T23:19:14.802Z">2025-12-14T23:19:14.802Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Now let me compile this into a comprehensive funding overview:</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-19-54-334Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-19-54-334Z" class="timestamp-link"><time datetime="2025-12-14T23:19:54.334Z" data-timestamp="2025-12-14T23:19:54.334Z">2025-12-14T23:19:54.334Z</time></a></div><div class="message-content"><div class="file-tool edit-tool" data-tool-id="toolu_01MLctuKZDRvNxn1PBFQbc93">
<div class="file-tool-header edit-header"><span class="file-tool-icon">âœï¸</span> Edit <span class="file-tool-path">multi-amplicon-platform-strategy.md</span></div>
<div class="file-tool-fullpath">/Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md</div>
<div class="truncatable"><div class="truncatable-content">
<div class="edit-section edit-old"><div class="edit-label">âˆ’</div><pre class="edit-content">## Funding Strategy

### R21 (Exploratory/Developmental)
- $275K/year for 2 years
- Good fit for methods development
- Lower preliminary data requirements
- Leads to R01 for full application

### Alternative Mechanisms
- R01 (if strong preliminary data)
- U01 (consortium/cooperative agreement)
- Foundation grants (Gates, Wellcome)
- LMIC-focused mechanisms</pre></div>
<div class="edit-section edit-new"><div class="edit-label">+</div><pre class="edit-content">## Funding Strategy

### NIH Mechanisms

#### 1. NIGMS Technology Development R21 (PAR-25-202) - STRONG FIT
**&#34;Technology Development Research for Establishing Feasibility and Proof of Concept&#34;**

| Feature | Details |
|---------|---------|
| Budget | $275K total over 2 years (max $200K/year direct) |
| Duration | 2 years |
| Next deadline | February 16, 2025, then standard cycles |
| Clinical trials | Not allowed |

**Why it fits:**
- Explicitly for &#34;laboratory instruments, algorithms and software, chemical reagents and processes&#34;
- Supports proof-of-concept for unproven technologies
- High-risk exploratory research encouraged
- No preliminary data required (actually discouraged!)

**Caution:**
- Cannot include projects with existing proof-of-concept data
- Must not address specific biological questions (methods only)
- Requires signed letter confirming responsiveness

**URL:** [PAR-25-202](https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html)

#### 2. Parent R21 (PA-25-304) - GOOD FIT
**Standard exploratory/developmental mechanism**

| Feature | Details |
|---------|---------|
| Budget | $275K total over 2 years |
| Duration | 2 years |
| Deadlines | Standard NIH cycles (Feb, Jun, Oct) |

**Why it fits:**
- More flexibility than PAR-25-202
- Can include some biological validation
- Can reference preliminary data
- Multiple ICs accept (NIAID, NICHD, etc.)

**URL:** [PA-25-304](https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html)

#### 3. NIGMS Focused Technology R01 (PAR-25-203) - FOR FOLLOW-UP
**&#34;Focused Technology Research and Development&#34;**

| Feature | Details |
|---------|---------|
| Budget | $500K/year (modular) |
| Duration | Up to 5 years |
| Stage | After proof-of-concept established |

**Why it fits (later):**
- Natural progression from R21
- For &#34;creating and validating a working prototype technology&#34;
- Supports dissemination and broad application

**URL:** [PAR-25-203](https://grants.nih.gov/grants/guide/pa-files/PAR-25-203.html)

#### 4. Administrative Supplement to Existing R01
If you have an active R01 (e.g., the FRESH grant), you can request:
- Technology application supplement
- Methods development add-on
- Faster timeline than new application

**Contact program officer first to discuss eligibility**

#### 5. Fogarty International Center - LMIC Component
**HIV-associated Research at LMIC Institutions**
- Deadline: December 8, 2025
- Supports building research networks in LMICs
- Could fund the Durban qPCR deployment component

**URL:** [Fogarty Programs](https://www.fic.nih.gov/Programs)

---

### Foundation Funding

#### 1. Gates Foundation - Grand Challenges - EXCELLENT FIT
**&#34;Accelerating Innovation in Vaginal Formulations to Support Women&#39;s Health&#34;**

| Feature | Details |
|---------|---------|
| Budget | $100,000 - $250,000 per project |
| Deadline | December 16, 2025 |
| Duration | Up to 2 years |
| Focus | LMICs, women-led teams prioritized |

**Why it fits:**
- Explicitly mentions vaginal microbiome
- Emphasizes scalable, low-cost solutions for LMICs
- HIV prevention context
- Your LMIC-deployable qPCR component is perfect

**Apply via:** Grand Challenges Africa or Grand Challenges South Africa portal (depending on location)

**URL:** [Grand Challenges Vaginal Health](https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-0)

#### 2. Gates Foundation - Global Health Discovery Collaboratory
**Platform access program**

| Feature | Details |
|---------|---------|
| Budget | Up to $250,000 |
| Duration | Up to 2 years |
| Focus | Vaginal microbiome, pregnancy outcomes |

**Why it fits:**
- Supports &#34;discovery of probiotic formulations&#34;
- &#34;Improved understanding of longitudinal microbiome dynamics&#34;
- Emphasizes lowering barriers to technology access

#### 3. Gates Foundation - $2.5B Women&#39;s Health Initiative
**Broader strategic investment (2024-2032)**

- Gynecological and menstrual health is priority area
- Strong emphasis on vaginal microbiome
- Diagnostics and therapeutic strategies
- Focus on resource-constrained settings

**Approach:** Contact Gates Foundation program officers; this may align with their strategic priorities for commissioned research.

#### 4. Wellcome Leap - FORM Program - EXPLORATORY
**&#34;Foundations of a Resilient Microbiome&#34;**

| Feature | Details |
|---------|---------|
| Budget | Part of $50M program |
| Focus | Gut microbiome (not vaginal) |
| Goals | Screening methods, diagnostic biomarkers |

**Why potentially relevant:**
- Methods for microbiome assessment
- Diagnostic biomarker development
- Could adapt vaginal microbiome work to their framework

**Note:** Currently gut-focused, but worth monitoring for expansion

**URL:** [Wellcome Leap FORM](https://wellcomeleap.org/form/)

#### 5. Novo Nordisk Foundation / Wellcome / Gates Partnership
**$300M Global Health R&amp;D Partnership (2024-2027)**

- First investment: AMR (Gr-ADI program)
- Future investments in infectious disease diagnostics possible
- LMIC-focused

**Worth monitoring for future calls**

---

### Recommended Funding Strategy

```
IMMEDIATE (2025)
â”œâ”€â”€ Gates Grand Challenges Vaginal Health
â”‚   â””â”€â”€ Deadline: December 16, 2025
â”‚   â””â”€â”€ Focus: LMIC qPCR component
â”‚   â””â”€â”€ Budget: $100-250K
â”‚
â”œâ”€â”€ NIGMS Technology Development R21 (PAR-25-202)
â”‚   â””â”€â”€ Deadline: February 16, 2025
â”‚   â””â”€â”€ Focus: Platform development (no biological questions)
â”‚   â””â”€â”€ Budget: $275K
â”‚
â””â”€â”€ Administrative Supplement (if eligible)
    â””â”€â”€ Contact program officer
    â””â”€â”€ Add methods development to existing award

FOLLOW-UP (2026-2027)
â”œâ”€â”€ Parent R21 or R01
â”‚   â””â”€â”€ With validation data from above
â”‚   â””â”€â”€ Include biological application
â”‚
â”œâ”€â”€ NIGMS Focused Technology R01 (PAR-25-203)
â”‚   â””â”€â”€ Full platform validation and dissemination
â”‚
â””â”€â”€ Fogarty mechanisms
    â””â”€â”€ LMIC capacity building
    â””â”€â”€ South African reference database
```

---

### Key Contacts to Make

1. **NIGMS Program Officer** - Discuss PAR-25-202 fit before submission
2. **NIAID Microbiome Program** - Potential interest in HIV/microbiome methods
3. **Gates Foundation Program Officer** - Women&#39;s health / global health diagnostics
4. **Fogarty International Center** - LMIC deployment component

---

### Budget Comparison

| Mechanism | Amount | Duration | Best For |
|-----------|--------|----------|----------|
| Gates Grand Challenges | $100-250K | 2 years | LMIC qPCR, field deployment |
| NIGMS Tech R21 | $275K | 2 years | Platform proof-of-concept |
| Parent R21 | $275K | 2 years | Methods + some validation |
| Admin Supplement | Variable | 1-2 years | Add to existing award |
| NIGMS Tech R01 | $2.5M | 5 years | Full development (later) |</pre></div>
</div><button class="expand-btn">Show more</button></div>
</div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-19-54-362Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-19-54-362Z" class="timestamp-link"><time datetime="2025-12-14T23:19:54.362Z" data-timestamp="2025-12-14T23:19:54.362Z">2025-12-14T23:19:54.362Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>The file /Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md has been updated. Here&#x27;s the result of running `cat -n` on a snippet of the edited file:
   356â†’4. Model system validation of functional candidates
   357â†’
   358â†’---
   359â†’
   360â†’## Funding Strategy
   361â†’
   362â†’### NIH Mechanisms
   363â†’
   364â†’#### 1. NIGMS Technology Development R21 (PAR-25-202) - STRONG FIT
   365â†’**&quot;Technology Development Research for Establishing Feasibility and Proof of Concept&quot;**
   366â†’
   367â†’| Feature | Details |
   368â†’|---------|---------|
   369â†’| Budget | $275K total over 2 years (max $200K/year direct) |
   370â†’| Duration | 2 years |
   371â†’| Next deadline | February 16, 2025, then standard cycles |
   372â†’| Clinical trials | Not allowed |
   373â†’
   374â†’**Why it fits:**
   375â†’- Explicitly for &quot;laboratory instruments, algorithms and software, chemical reagents and processes&quot;
   376â†’- Supports proof-of-concept for unproven technologies
   377â†’- High-risk exploratory research encouraged
   378â†’- No preliminary data required (actually discouraged!)
   379â†’
   380â†’**Caution:**
   381â†’- Cannot include projects with existing proof-of-concept data
   382â†’- Must not address specific biological questions (methods only)
   383â†’- Requires signed letter confirming responsiveness
   384â†’
   385â†’**URL:** [PAR-25-202](https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html)
   386â†’
   387â†’#### 2. Parent R21 (PA-25-304) - GOOD FIT
   388â†’**Standard exploratory/developmental mechanism**
   389â†’
   390â†’| Feature | Details |
   391â†’|---------|---------|
   392â†’| Budget | $275K total over 2 years |
   393â†’| Duration | 2 years |
   394â†’| Deadlines | Standard NIH cycles (Feb, Jun, Oct) |
   395â†’
   396â†’**Why it fits:**
   397â†’- More flexibility than PAR-25-202
   398â†’- Can include some biological validation
   399â†’- Can reference preliminary data
   400â†’- Multiple ICs accept (NIAID, NICHD, etc.)
   401â†’
   402â†’**URL:** [PA-25-304](https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html)
   403â†’
   404â†’#### 3. NIGMS Focused Technology R01 (PAR-25-203) - FOR FOLLOW-UP
   405â†’**&quot;Focused Technology Research and Development&quot;**
   406â†’
   407â†’| Feature | Details |
   408â†’|---------|---------|
   409â†’| Budget | $500K/year (modular) |
   410â†’| Duration | Up to 5 years |
   411â†’| Stage | After proof-of-concept established |
   412â†’
   413â†’**Why it fits (later):**
   414â†’- Natural progression from R21
   415â†’- For &quot;creating and validating a working prototype technology&quot;
   416â†’- Supports dissemination and broad application
   417â†’
   418â†’**URL:** [PAR-25-203](https://grants.nih.gov/grants/guide/pa-files/PAR-25-203.html)
   419â†’
   420â†’#### 4. Administrative Supplement to Existing R01
   421â†’If you have an active R01 (e.g., the FRESH grant), you can request:
   422â†’- Technology application supplement
   423â†’- Methods development add-on
   424â†’- Faster timeline than new application
   425â†’
   426â†’**Contact program officer first to discuss eligibility**
   427â†’
   428â†’#### 5. Fogarty International Center - LMIC Component
   429â†’**HIV-associated Research at LMIC Institutions**
   430â†’- Deadline: December 8, 2025
   431â†’- Supports building research networks in LMICs
   432â†’- Could fund the Durban qPCR deployment component
   433â†’
   434â†’**URL:** [Fogarty Programs](https://www.fic.nih.gov/Programs)
   435â†’
   436â†’---
   437â†’
   438â†’### Foundation Funding
   439â†’
   440â†’#### 1. Gates Foundation - Grand Challenges - EXCELLENT FIT
   441â†’**&quot;Accelerating Innovation in Vaginal Formulations to Support Women&#x27;s Health&quot;**
   442â†’
   443â†’| Feature | Details |
   444â†’|---------|---------|
   445â†’| Budget | $100,000 - $250,000 per project |
   446â†’| Deadline | December 16, 2025 |
   447â†’| Duration | Up to 2 years |
   448â†’| Focus | LMICs, women-led teams prioritized |
   449â†’
   450â†’**Why it fits:**
   451â†’- Explicitly mentions vaginal microbiome
   452â†’- Emphasizes scalable, low-cost solutions for LMICs
   453â†’- HIV prevention context
   454â†’- Your LMIC-deployable qPCR component is perfect
   455â†’
   456â†’**Apply via:** Grand Challenges Africa or Grand Challenges South Africa portal (depending on location)
   457â†’
   458â†’**URL:** [Grand Challenges Vaginal Health](https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-0)
   459â†’
   460â†’#### 2. Gates Foundation - Global Health Discovery Collaboratory
   461â†’**Platform access program**
   462â†’
   463â†’| Feature | Details |
   464â†’|---------|---------|
   465â†’| Budget | Up to $250,000 |
   466â†’| Duration | Up to 2 years |
   467â†’| Focus | Vaginal microbiome, pregnancy outcomes |
   468â†’
   469â†’**Why it fits:**
   470â†’- Supports &quot;discovery of probiotic formulations&quot;
   471â†’- &quot;Improved understanding of longitudinal microbiome dynamics&quot;
   472â†’- Emphasizes lowering barriers to technology access
   473â†’
   474â†’#### 3. Gates Foundation - $2.5B Women&#x27;s Health Initiative
   475â†’**Broader strategic investment (2024-2032)**
   476â†’
   477â†’- Gynecological and menstrual health is priority area
   478â†’- Strong emphasis on vaginal microbiome
   479â†’- Diagnostics and therapeutic strategies
   480â†’- Focus on resource-constrained settings
   481â†’
   482â†’**Approach:** Contact Gates Foundation program officers; this may align with their strategic priorities for commissioned research.
   483â†’
   484â†’#### 4. Wellcome Leap - FORM Program - EXPLORATORY
   485â†’**&quot;Foundations of a Resilient Microbiome&quot;**
   486â†’
   487â†’| Feature | Details |
   488â†’|---------|---------|
   489â†’| Budget | Part of $50M program |
   490â†’| Focus | Gut microbiome (not vaginal) |
   491â†’| Goals | Screening methods, diagnostic biomarkers |
   492â†’
   493â†’**Why potentially relevant:**
   494â†’- Methods for microbiome assessment
   495â†’- Diagnostic biomarker development
   496â†’- Could adapt vaginal microbiome work to their framework
   497â†’
   498â†’**Note:** Currently gut-focused, but worth monitoring for expansion
   499â†’
   500â†’**URL:** [Wellcome Leap FORM](https://wellcomeleap.org/form/)
   501â†’
   502â†’#### 5. Novo Nordisk Foundation / Wellcome / Gates Partnership
   503â†’**$300M Global Health R&amp;D Partnership (2024-2027)**
   504â†’
   505â†’- First investment: AMR (Gr-ADI program)
   506â†’- Future investments in infectious disease diagnostics possible
   507â†’- LMIC-focused
   508â†’
   509â†’**Worth monitoring for future calls**
   510â†’
   511â†’---
   512â†’
   513â†’### Recommended Funding Strategy
   514â†’
   515â†’```
   516â†’IMMEDIATE (2025)
   517â†’â”œâ”€â”€ Gates Grand Challenges Vaginal Health
   518â†’â”‚   â””â”€â”€ Deadline: December 16, 2025
   519â†’â”‚   â””â”€â”€ Focus: LMIC qPCR component
   520â†’â”‚   â””â”€â”€ Budget: $100-250K
   521â†’â”‚
   522â†’â”œâ”€â”€ NIGMS Technology Development R21 (PAR-25-202)
   523â†’â”‚   â””â”€â”€ Deadline: February 16, 2025
   524â†’â”‚   â””â”€â”€ Focus: Platform development (no biological questions)
   525â†’â”‚   â””â”€â”€ Budget: $275K
   526â†’â”‚
   527â†’â””â”€â”€ Administrative Supplement (if eligible)
   528â†’    â””â”€â”€ Contact program officer
   529â†’    â””â”€â”€ Add methods development to existing award
   530â†’
   531â†’FOLLOW-UP (2026-2027)
   532â†’â”œâ”€â”€ Parent R21 or R01
   533â†’â”‚   â””â”€â”€ With validation data from above
   534â†’â”‚   â””â”€â”€ Include biological application
   535â†’â”‚
   536â†’â”œâ”€â”€ NIGMS Focused Technology R01 (PAR-25-203)
   537â†’â”‚   â””â”€â”€ Full platform validation and dissemination
   538â†’â”‚
   539â†’â””â”€â”€ Fogarty mechanisms
   540â†’    â””â”€â”€ LMIC capacity building
   541â†’    â””â”€â”€ South African reference database
   542â†’```
   543â†’
   544â†’---
   545â†’
   546â†’### Key Contacts to Make
   547â†’
   548â†’1. **NIGMS Program Officer** - Discuss PAR-25-202 fit before submission
   549â†’2. **NIAID Microbiome Program** - Potential interest in HIV/microbiome methods
   550â†’3. **Gates Foundation Program Officer** - Women&#x27;s health / global health diagnostics
   551â†’4. **Fogarty International Center** - LMIC deployment component
   552â†’
   553â†’---
   554â†’
   555â†’### Budget Comparison
   556â†’
   557â†’| Mechanism | Amount | Duration | Best For |
   558â†’|-----------|--------|----------|----------|
   559â†’| Gates Grand Challenges | $100-250K | 2 years | LMIC qPCR, field deployment |
   560â†’| NIGMS Tech R21 | $275K | 2 years | Platform proof-of-concept |
   561â†’| Parent R21 | $275K | 2 years | Methods + some validation |
   562â†’| Admin Supplement | Variable | 1-2 years | Add to existing award |
   563â†’| NIGMS Tech R01 | $2.5M | 5 years | Full development (later) |
   564â†’
   565â†’---
   566â†’
   567â†’## Key Innovation Points</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-20-14-009Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-20-14-009Z" class="timestamp-link"><time datetime="2025-12-14T23:20:14.009Z" data-timestamp="2025-12-14T23:20:14.009Z">2025-12-14T23:20:14.009Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>I've saved the strategy document and updated it with comprehensive funding information. Here's a summary:</p>
<hr />
<h2>Funding Opportunities Summary</h2>
<h3>Immediate Opportunities (Deadlines in 2025)</h3>
<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Deadline</th>
<th>Budget</th>
<th>Best Fit</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong><a href="https://gcgh.grandchallenges.org/challenge/accelerating-innovation-vaginal-formulations-support-womens-health-0">Gates Grand Challenges - Vaginal Health</a></strong></td>
<td>Dec 16, 2025</td>
<td>$100-250K</td>
<td>LMIC qPCR deployment</td>
</tr>
<tr>
<td><strong><a href="https://grants.nih.gov/grants/guide/pa-files/PAR-25-202.html">NIGMS Tech R21 (PAR-25-202)</a></strong></td>
<td>Feb 16, 2025</td>
<td>$275K</td>
<td>Pure methods development</td>
</tr>
<tr>
<td><strong><a href="https://grants.nih.gov/grants/guide/pa-files/PA-25-304.html">Parent R21 (PA-25-304)</a></strong></td>
<td>Feb/Jun/Oct</td>
<td>$275K</td>
<td>Methods + validation</td>
</tr>
</tbody>
</table>
<h3>Key Findings</h3>
<p><strong>1. NIGMS Technology Development R21 (PAR-25-202)</strong> - Very strong fit but with a catch:
- Explicitly supports "algorithms and software, chemical reagents and processes"
- <strong>No preliminary data allowed</strong> - must be pure proof-of-concept
- Cannot address specific biological questions
- Perfect for: UMI pipeline development, multi-marker concordance algorithms, functional scoring</p>
<p><strong>2. Gates Grand Challenges</strong> - Excellent for LMIC component:
- Currently open call for vaginal health innovations
- Emphasizes scalable, low-cost solutions
- Prioritizes LMIC- and women-led teams
- Your qPCR derivative is exactly what they're looking for</p>
<p><strong>3. Gates $2.5B Women's Health Initiative</strong> - Strategic alignment:
- Vaginal microbiome is explicitly called out as priority
- Diagnostics and therapeutic strategies
- Could be larger commissioned research opportunity</p>
<p><strong>4. Administrative Supplement</strong> - Fastest path if eligible:
- Add methods development to your existing FRESH R01
- Contact program officer to discuss</p>
<h3>Recommended Strategy</h3>
<pre><code>PARALLEL TRACKS

Track 1: Gates Grand Challenges (Dec 2025)
â”œâ”€â”€ Focus: LMIC-deployable qPCR panel
â”œâ”€â”€ Partner: South African collaborators
â”œâ”€â”€ Budget: $100-250K
â””â”€â”€ Outcome: Field validation, capacity building

Track 2: NIGMS Tech R21 (Feb 2025)
â”œâ”€â”€ Focus: Multi-amplicon bioinformatics platform
â”œâ”€â”€ Pure methods (no biological questions)
â”œâ”€â”€ Budget: $275K
â””â”€â”€ Outcome: Pipeline development, UMI processing

Track 3: Methods Publication (parallel)
â”œâ”€â”€ Validates platform
â”œâ”€â”€ Builds preliminary data
â””â”€â”€ Enables Parent R21/R01 for biological application

Track 4: Follow-up R01 (2026-2027)
â”œâ”€â”€ NIGMS Tech R01 (PAR-25-203)
â”œâ”€â”€ Full platform with biological validation
â””â”€â”€ Application to FRESH cohort
</code></pre>
<h3>Important Note on PAR-25-202</h3>
<p>The NIGMS Technology R21 has a strict requirement: <strong>applications with preliminary data supporting proof-of-concept will be withdrawn without review</strong>. This means:</p>
<ul>
<li><strong>Good for:</strong> Novel bioinformatics approaches (UMI integration, multi-marker concordance)</li>
<li><strong>Not good for:</strong> Validating existing primer sets or established methods</li>
<li>You'd need to frame this as developing novel computational methods, not validating amplicon approaches</li>
</ul>
<p>The Parent R21 (PA-25-304) is more flexible if you have any preliminary data.</p>
<hr />
<p>The document is saved at <code>/Users/scotthandley/Code/novel-FGT-approaches/multi-amplicon-platform-strategy.md</code> with the full funding details.</p>
<p><strong>Questions:</strong></p>
<ol>
<li>Is the Gates deadline (Dec 16, 2025) feasible for a submission? That's very soon.</li>
<li>Do you have an active R01 that could support an administrative supplement?</li>
<li>For the NIGMS Tech R21, would you want to frame this around the bioinformatics innovation (UMI, multi-marker concordance) to avoid the preliminary data restriction?</li>
</ol></div></div></div>
<div class="message user" id="msg-2025-12-14T23-24-07-012Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T23-24-07-012Z" class="timestamp-link"><time datetime="2025-12-14T23:24:07.012Z" data-timestamp="2025-12-14T23:24:07.012Z">2025-12-14T23:24:07.012Z</time></a></div><div class="message-content">
<div class="user-content"><p>What about standard R21</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-24-27-847Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-24-27-847Z" class="timestamp-link"><time datetime="2025-12-14T23:24:27.847Z" data-timestamp="2025-12-14T23:24:27.847Z">2025-12-14T23:24:27.847Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Good question. The <strong>Parent R21 (PA-25-304)</strong> is actually the better fit for your situation. Let me compare:</p>
<h2>Parent R21 vs. NIGMS Tech R21</h2>
<table>
<thead>
<tr>
<th>Feature</th>
<th>Parent R21 (PA-25-304)</th>
<th>NIGMS Tech R21 (PAR-25-202)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Preliminary data</strong></td>
<td>Allowed and helpful</td>
<td><strong>Prohibited</strong> - will be withdrawn</td>
</tr>
<tr>
<td><strong>Biological questions</strong></td>
<td>Allowed</td>
<td><strong>Not allowed</strong> - methods only</td>
</tr>
<tr>
<td><strong>Scope</strong></td>
<td>Flexible</td>
<td>Narrow (pure tech dev)</td>
</tr>
<tr>
<td><strong>Budget</strong></td>
<td>$275K / 2 years</td>
<td>$275K / 2 years</td>
</tr>
<tr>
<td><strong>Deadlines</strong></td>
<td>Feb 16, Jun 16, Oct 16</td>
<td>Feb 16, Jun 16, Oct 16</td>
</tr>
<tr>
<td><strong>ICs that accept</strong></td>
<td>Most (NIAID, NICHD, NCI, etc.)</td>
<td>NIGMS only</td>
</tr>
</tbody>
</table>
<h2>Why Parent R21 is Better for You</h2>
<p><strong>1. You have preliminary data</strong>
- Your 16S V4 cervicotype work
- Metabolomics showing biogenic amines
- Strain structure in L. crispatus (Fig 3 in grant)
- This strengthens a Parent R21 but disqualifies PAR-25-202</p>
<p><strong>2. You want biological validation</strong>
- Test platform on FRESH samples
- Correlate with cytokines, HIV outcomes
- PAR-25-202 explicitly prohibits this</p>
<p><strong>3. Multiple ICs could fund it</strong>
- NIAID (HIV, infectious disease)
- NICHD (women's reproductive health)
- NCI (methods development interest)</p>
<p><strong>4. Natural path to R01</strong>
- Parent R21 â†’ preliminary data â†’ R01
- More straightforward than tech-only pathway</p>
<h2>Parent R21 Specific Aims (Draft)</h2>
<pre><code>Aim 1: Develop and optimize a multi-amplicon sequencing platform 
       for high-resolution FGT microbiome profiling

       1.1: Validate cpn60 and rpoB amplicons with UMI tagging
       1.2: Design and optimize functional gene panel (nanH, vly, 
            speA, ldcC, ldhD, ily, ldhL)
       1.3: Develop multiplexing strategy for iSeq/NovaSeq

Aim 2: Create bioinformatics pipeline for multi-marker integration 
       and functional scoring

       2.1: UMI-based error correction and strain deconvolution
       2.2: Multi-marker taxonomic concordance algorithm
       2.3: Functional inflammation/protection scoring

Aim 3: Validate platform performance against established methods 
       in FGT samples

       3.1: Compare to 16S V4 cervicotype assignments (n=100-200)
       3.2: Correlate functional scores with cytokine data
       3.3: Develop LMIC-deployable qPCR derivative
</code></pre>
<h2>Timeline Consideration</h2>
<table>
<thead>
<tr>
<th>Deadline</th>
<th>Date</th>
<th>Feasibility</th>
</tr>
</thead>
<tbody>
<tr>
<td>February 2025</td>
<td>~2 months</td>
<td>Tight but doable</td>
</tr>
<tr>
<td>June 2025</td>
<td>~6 months</td>
<td>Comfortable</td>
</tr>
<tr>
<td>October 2025</td>
<td>~10 months</td>
<td>Very comfortable</td>
</tr>
</tbody>
</table>
<h2>Recommendation</h2>
<p><strong>Submit Parent R21 to NIAID for June 2025 deadline:</strong>
- Gives time to develop strong application
- Can include your existing preliminary data
- Frame around HIV acquisition risk (NIAID priority)
- Include LMIC deployment component (aligns with Fogarty interests)</p>
<p><strong>Parallel:</strong> Apply to Gates Grand Challenges by Dec 16 for the qPCR/LMIC component - these are complementary, not competing.</p>
<p>Would you like me to draft a more detailed specific aims page for the Parent R21?</p></div></div></div>
<div class="message user" id="msg-2025-12-14T23-28-42-750Z"><div class="message-header"><span class="role-label">User</span><a href="#msg-2025-12-14T23-28-42-750Z" class="timestamp-link"><time datetime="2025-12-14T23:28:42.750Z" data-timestamp="2025-12-14T23:28:42.750Z">2025-12-14T23:28:42.750Z</time></a></div><div class="message-content">
<div class="user-content"><p>great. can you save a new markdown document documenting these ideas towards the Parent R21</p></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-30-18-734Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-30-18-734Z" class="timestamp-link"><time datetime="2025-12-14T23:30:18.734Z" data-timestamp="2025-12-14T23:30:18.734Z">2025-12-14T23:30:18.734Z</time></a></div><div class="message-content"><div class="file-tool write-tool" data-tool-id="toolu_019g8DYknYyJLkUF8WTc8g9c">
<div class="file-tool-header write-header"><span class="file-tool-icon">ğŸ“</span> Write <span class="file-tool-path">parent-R21-proposal.md</span></div>
<div class="file-tool-fullpath">/Users/scotthandley/Code/novel-FGT-approaches/parent-R21-proposal.md</div>
<div class="truncatable"><div class="truncatable-content"><pre class="file-content"># Parent R21 Proposal: Multi-Amplicon FGT Microbiome Profiling Platform

## Administrative Information

| Field | Details |
|-------|---------|
| **Mechanism** | R21 Exploratory/Developmental Research Grant |
| **FOA** | PA-25-304 (Clinical Trial Not Allowed) |
| **Target IC** | NIAID (primary), NICHD (secondary) |
| **Budget** | $275,000 total costs over 2 years |
| **Target Deadline** | June 16, 2025 |
| **PI** | Scott Handley, PhD |
| **Institution** | Washington University in St. Louis |

---

## Project Title Options

1. &#34;A Multi-Amplicon Platform for High-Resolution Female Genital Tract Microbiome Profiling&#34;
2. &#34;Integrated Multi-Gene Amplicon Sequencing for Species-Level Vaginal Microbiome Characterization&#34;
3. &#34;Cost-Effective Multi-Marker Microbiome Profiling to Assess HIV Acquisition Risk in Women&#34;

---

## Specific Aims

### Background (for Aims page)

The female genital tract (FGT) microbiome plays a critical role in HIV acquisition risk. Our prior work demonstrated that high-diversity vaginal bacterial communities with low Lactobacillus abundance are associated with a &gt;4-fold increased risk of HIV acquisition in young South African women. However, current profiling methods have significant limitations: 16S rRNA sequencing cannot reliably distinguish Gardnerella species or Lactobacillus strains, while shotgun metagenomics is prohibitively expensive for large cohorts due to high host DNA contamination in FGT samples.

We propose to develop a multi-amplicon sequencing platform that achieves species and strain-level resolution at a fraction of metagenomics costs, while providing direct functional readouts of inflammation-associated genes. This platform will enable large-scale studies of microbiome-mediated HIV risk and provide a path toward field-deployable diagnostics for low- and middle-income countries (LMICs) where HIV burden is greatest.

### Aim 1: Develop and optimize a multi-amplicon sequencing platform for high-resolution FGT microbiome profiling

**Rationale:** Standard 16S rRNA sequencing cannot distinguish Gardnerella species (&gt;98.5% 16S identity) or resolve Lactobacillus strains that may differ in inflammatory potential. Alternative markers (cpn60, rpoB) provide superior resolution but have not been systematically combined for vaginal microbiome profiling.

**Approach:**
- **1.1:** Validate cpn60 universal target primers with UMI tagging for species-level resolution and strain deconvolution of Gardnerella and Lactobacillus
- **1.2:** Design and optimize rpoB primers using DPO (dual priming oligonucleotide) technology for orthogonal taxonomic validation
- **1.3:** Design functional gene amplicon panel targeting inflammation-associated genes:
  - Sialidases (nanH1/nanH2) - mucin degradation
  - Vaginolysin (vly) - cytolysis, PAMP release
  - Inerolysin (ily) - L. iners virulence marker
  - Biogenic amine synthesis (speA/odc, ldcC) - putrescine, cadaverine production
  - D-lactate dehydrogenase (ldhD) - protective L. crispatus marker
  - L-lactate dehydrogenase (ldhL) - ratio to ldhD informative
- **1.4:** Optimize multiplexing strategy for Illumina iSeq/NovaSeq platforms

**Expected outcomes:** Validated primer sets, optimized PCR conditions, multiplexing protocol

### Aim 2: Create bioinformatics pipeline for multi-marker integration and functional scoring

**Rationale:** No existing pipeline integrates multiple taxonomic markers with functional gene quantification. Novel algorithms are needed for UMI-based error correction, multi-marker concordance, and composite functional scoring.

**Approach:**
- **2.1:** Develop UMI processing module for cpn60 and rpoB amplicons
  - Consensus sequence generation from UMI families
  - PCR chimera elimination
  - Absolute molecule counting
- **2.2:** Create multi-marker taxonomic concordance algorithm
  - Compare taxonomic assignments across 16S V4, 16S V1-V3, cpn60, and rpoB
  - Generate confidence-weighted consensus taxonomy
  - Flag discordances indicating novel taxa or database gaps
- **2.3:** Implement functional scoring system
  - Normalize functional gene abundances to spike-in standards
  - Calculate &#34;Inflammation Potential Score&#34; from nanH, vly, speA, ldcC
  - Calculate &#34;Protection Score&#34; from ldhD and Lactobacillus abundance
  - Derive composite &#34;Risk Index&#34;
- **2.4:** Build reference database framework integrating public data (cpnDB, VOGUE) with capacity to incorporate South African isolate sequences

**Expected outcomes:** Open-source bioinformatics pipeline, reference databases, functional scoring algorithms

### Aim 3: Validate platform performance and develop LMIC-deployable derivative

**Rationale:** Platform validation against established methods is essential before large-scale application. Additionally, the same primer binding sites can enable low-cost qPCR assays deployable in resource-limited settings.

**Approach:**
- **3.1:** Validate on archived FGT samples (n=100-200) with existing 16S V4 data
  - Compare species calls to cervicotype assignments
  - Assess reproducibility and technical variation
  - Evaluate spike-in normalization for absolute quantification
- **3.2:** Correlate functional scores with host inflammatory markers
  - Compare to Luminex cytokine data from same samples
  - Test association with cervical CD4+ T cell counts
  - Preliminary assessment of HIV acquisition association
- **3.3:** Develop qPCR derivative for LMIC deployment
  - Convert sequencing primers to qPCR format (same binding sites)
  - Optimize multiplex qPCR panel (4-6 targets)
  - Validate against sequencing results
  - Document protocol for field deployment

**Expected outcomes:** Validated platform, correlation with host inflammation, LMIC-ready qPCR protocol

---

## Significance

### Scientific Significance

1. **Addresses critical methodological gap:** Current 16S sequencing cannot resolve species/strains most relevant to FGT health and HIV risk. Metagenomics is too expensive for population-scale studies.

2. **Enables mechanistic studies:** Direct quantification of functional genes (sialidases, cytolysins, biogenic amine synthesis) provides mechanistic readouts without metagenomics.

3. **Supports absolute quantification:** UMI-based molecule counting combined with spike-in normalization enables comparison across samples with varying biomass.

4. **Builds population-specific resources:** Framework for South African reference database addresses bias in existing resources toward North American/European populations.

### Public Health Significance

1. **HIV prevention:** Understanding microbiome contributions to HIV acquisition risk is critical for developing prevention strategies in sub-Saharan Africa where burden is highest.

2. **LMIC deployment:** qPCR derivative enables risk stratification in clinical settings with basic molecular biology infrastructure.

3. **Scalability:** Platform enables large cohort studies (thousands of samples) at costs compatible with NIH-funded research.

---

## Innovation

1. **Multi-marker taxonomic integration:** First systematic combination of cpn60, rpoB, and 16S for vaginal microbiome with concordance-based confidence scoring.

2. **UMI-tagged amplicons for FGT:** Novel application of UMI technology to vaginal microbiome for strain deconvolution and absolute quantification.

3. **Functional gene amplicons:** Direct PCR-based quantification of inflammation-associated genes as alternative to metagenomics/metatranscriptomics.

4. **Dual-use design:** Same primer binding sites enable both high-resource sequencing and LMIC-deployable qPCR.

5. **Composite functional scoring:** Novel algorithmic approach to derive inflammation/protection indices from multi-gene data.

---

## Preliminary Data

### 1. Cervicotype associations with HIV acquisition (Published)

Our prior work in the FRESH cohort demonstrated:
- Four cervicotypes defined by 16S V4 sequencing
- CT3/CT4 (high diversity, low Lactobacillus) associated with &gt;4-fold increased HIV risk
- Elevated inflammatory cytokines in CT3/CT4
- 17-fold increase in cervical HIV target cells (activated CD4+ T cells)

*Gosmann et al., Immunity 2017; Anahtar et al., Immunity 2015*

### 2. Metabolomic signatures (Preliminary)

Metabolomics from 143 FRESH participants showed:
- Elevated putrescine and cadaverine in CT3/CT4
- These biogenic amines have documented pro-inflammatory and pro-viral effects
- Supports targeting speA/odc and ldcC genes in functional panel

### 3. Strain-level structure (Preliminary)

Initial shotgun metagenomic data from FRESH shows:
- Geographic distribution of L. crispatus strains between South Africa and North America
- Supports need for population-specific reference data
- Validates utility of strain-resolution approach

### 4. Existing validated primers

We have validated primer sets for:
- 16S V4 (Earth Microbiome Project 515F/806R)
- 16S V1-V3 (Ravel lab validated for vaginal samples)
- ITS2 for fungal profiling
- Zymo spike-in standards for absolute quantification

---

## Approach

### Amplicon Panel Design

| Amplicon | Primers | Length | UMI | Purpose |
|----------|---------|--------|-----|---------|
| 16S V4 | 515F/806R (have) | ~250bp | No | Cross-study compatibility |
| 16S V1-V3 | Ravel set (have) | ~500bp | No | Lactobacillus resolution |
| cpn60 UT | H279p/H280p + UMI | ~550bp | Yes | Species/strain resolution |
| rpoB | De novo design (DPO) | ~350-550bp | Yes | Orthogonal validation |
| nanH | De novo design | ~300-400bp | No | Sialidase quantification |
| vly | De novo design | ~300-400bp | No | Vaginolysin quantification |
| ily | De novo design | ~300-400bp | No | Inerolysin quantification |
| speA/odc | De novo design | ~300-400bp | No | Putrescine synthesis |
| ldcC | De novo design | ~300-400bp | No | Cadaverine synthesis |
| ldhD | De novo design | ~300-400bp | No | D-lactate (protective) |
| ldhL | De novo design | ~300-400bp | No | L-lactate (ratio) |

### Primer Design Strategy

**For cpn60:** Use established H279p/H280p primers with added UMI + Illumina adapter tails

**For rpoB:** De novo design using:
1. Download Lactobacillus, Gardnerella, Prevotella genomes from NCBI
2. Extract rpoB sequences computationally
3. Align with MUSCLE/MAFFT
4. Design primers using DegePrime for degenerate optimization
5. Use DPO format for enhanced specificity

**For functional genes:**
1. Curate sequences from NCBI/UniProt
2. Include known variants
3. Design broad primers capturing diversity
4. Validate in silico against FGT reference genomes

### Multiplexing Strategy

```
Pool 1: Taxonomic markers (same target gene families)
â”œâ”€â”€ 16S V4 + 16S V1-V3

Pool 2: Alternative taxonomic markers
â”œâ”€â”€ cpn60 (UMI) + rpoB (UMI)

Pool 3: Functional genes
â”œâ”€â”€ nanH + vly + ily + speA + ldcC + ldhD + ldhL
```

### Sequencing Strategy

| Phase | Platform | Samples | Reads/sample | Purpose |
|-------|----------|---------|--------------|---------|
| Optimization | iSeq | Mock communities | 100K | Protocol development |
| Validation | NovaSeq | n=100-200 FRESH | 300-500K | Platform validation |

### Bioinformatics Pipeline Architecture

```
INPUT: Multiplexed amplicon reads
       â†“
DEMULTIPLEXING
â”œâ”€â”€ By sample (dual index)
â”œâ”€â”€ By amplicon (primer sequence)
â””â”€â”€ By molecule (UMI, for cpn60/rpoB)
       â†“
AMPLICON-SPECIFIC PROCESSING
â”œâ”€â”€ 16S V4: DADA2 â†’ GreenGenes2
â”œâ”€â”€ 16S V1-V3: DADA2 â†’ SILVA + custom DB
â”œâ”€â”€ cpn60: UMI consensus â†’ cpnDB + VOGUE
â”œâ”€â”€ rpoB: UMI consensus â†’ Custom DB
â””â”€â”€ Functional: Quantify â†’ Normalize to spike-in
       â†“
INTEGRATION
â”œâ”€â”€ Taxonomic concordance scoring
â”œâ”€â”€ Spike-in normalization
â”œâ”€â”€ Functional gene quantification
â””â”€â”€ Composite scoring
       â†“
OUTPUT
â”œâ”€â”€ Per-sample profiles
â”œâ”€â”€ QC reports
â””â”€â”€ Visualization
```

### Validation Samples

From archived FRESH samples:
- n=100-200 with existing 16S V4 data
- Spanning all four cervicotypes
- Subset with matched cytokine data
- Subset with matched flow cytometry

### qPCR Development

Convert sequencing primers to qPCR:
```
Sequencing: 5&#39;-[Illumina adapter]-[UMI]-[GENE-SPECIFIC]-3&#39;
qPCR:       5&#39;-[GENE-SPECIFIC]-3&#39; (same binding site)
Probe:      5&#39;-[FAM]-[Internal sequence]-[BHQ]-3&#39;
```

Target panel for LMIC:
1. Total bacterial load (universal)
2. L. crispatus
3. L. iners
4. Gardnerella (genus)
5. Sialidase (nanH)
6. ldhD (protective marker)

---

## Timeline

### Year 1 (Months 1-12)

| Months | Activity | Deliverable |
|--------|----------|-------------|
| 1-3 | Primer design and synthesis | Validated primer sequences |
| 2-4 | Build reference databases from public data | cpn60, rpoB, functional gene DBs |
| 3-5 | Optimize individual amplicon PCRs | SOPs for each amplicon |
| 4-6 | Develop UMI processing pipeline | Working bioinformatics module |
| 5-7 | Optimize multiplexing | Final pooling strategy |
| 6-9 | Validate on mock communities | Technical performance metrics |
| 8-12 | Process validation samples (n=100) | Initial validation dataset |
| 10-12 | Develop concordance algorithm | Multi-marker integration tool |

### Year 2 (Months 13-24)

| Months | Activity | Deliverable |
|--------|----------|-------------|
| 13-16 | Complete validation (n=200 total) | Full validation dataset |
| 14-18 | Correlate with cytokine/flow data | Functional score validation |
| 16-20 | Develop qPCR derivative | LMIC-ready protocol |
| 18-22 | Validate qPCR against sequencing | qPCR performance data |
| 20-24 | Finalize pipeline and documentation | Public release |
| 22-24 | Prepare methods manuscript | Submitted publication |

---

## Budget Justification

### Year 1: $137,500 direct costs

| Category | Amount | Justification |
|----------|--------|---------------|
| Personnel | $80,000 | Postdoc (50% effort) - primer design, wet lab optimization, pipeline development |
| Supplies | $35,000 | Primer synthesis ($5K), library prep reagents ($20K), extraction/PCR supplies ($10K) |
| Sequencing | $15,000 | iSeq runs for optimization, NovaSeq for initial validation |
| Other | $7,500 | Computing costs, database hosting, mock community purchase |

### Year 2: $137,500 direct costs

| Category | Amount | Justification |
|----------|--------|---------------|
| Personnel | $80,000 | Postdoc (50% effort) - validation, qPCR development, manuscript preparation |
| Supplies | $30,000 | Library prep for validation samples, qPCR reagents and optimization |
| Sequencing | $20,000 | NovaSeq for full validation set |
| Other | $7,500 | Computing, publication costs, database maintenance |

---

## Expected Outcomes

### Primary Deliverables

1. **Validated multi-amplicon panel** for FGT microbiome profiling with species/strain resolution
2. **Open-source bioinformatics pipeline** for multi-marker integration and functional scoring
3. **Reference databases** for cpn60, rpoB, and functional genes incorporating public data
4. **LMIC-deployable qPCR protocol** using same primer binding sites
5. **Methods publication** describing platform and validation

### Metrics of Success

| Metric | Target |
|--------|--------|
| Species-level concordance (cpn60 vs rpoB) | &gt;90% |
| Gardnerella species resolution | 4+ species distinguished |
| Lactobacillus strain detection | Intra-sample mixtures resolved |
| Functional score correlation with cytokines | r &gt; 0.5 |
| qPCR vs sequencing concordance | r &gt; 0.85 |
| Cost per sample (full panel) | &lt;$100 |
| Cost per sample (qPCR) | &lt;$25 |

---

## Future Directions

This R21 will enable:

1. **R01 application** for full-scale FRESH cohort profiling (n=3600 samples)
2. **South African reference database** from cultured isolates
3. **Clinical translation** of qPCR panel for HIV risk stratification
4. **Mechanistic studies** using functional gene candidates identified
5. **Extension to other cohorts** studying FGT microbiome and women&#39;s health

---

## Relevance to NIAID Mission

This project directly addresses NIAID priorities:

1. **HIV prevention research** - Understanding microbiome contributions to acquisition risk
2. **Global health** - LMIC-deployable diagnostics for sub-Saharan Africa
3. **Methods development** - Novel approaches for microbiome characterization
4. **Genomic technologies** - Advancing amplicon sequencing capabilities

---

## Alternative IC Considerations

### NICHD (Secondary option)
- Women&#39;s reproductive health focus
- Interest in vaginal microbiome
- Less HIV-specific framing needed

### NCI (If applicable)
- Methods development interest
- Microbiome profiling technologies
- Could frame around HPV/cervical cancer if relevant

---

## Key References

1. Gosmann C, et al. Lactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. *Immunity* 2017.

2. Anahtar MN, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. *Immunity* 2015.

3. Links MG, et al. The chaperonin-60 universal target is a barcode for bacteria that enables de novo assembly of metagenomic sequence data. *PLoS One* 2012.

4. Callahan BJ, et al. High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. *Nucleic Acids Res* 2019.

5. Karst SM, et al. High-accuracy long-read amplicon sequences using unique molecular identifiers with Nanopore or PacBio sequencing. *Nat Methods* 2021.

---

## Document Information

| Field | Value |
|-------|-------|
| Created | December 2025 |
| Version | 1.0 |
| Status | Draft for discussion |
| Related documents | multi-amplicon-platform-strategy.md |

---

## Next Steps

1. [ ] Confirm target IC (NIAID vs NICHD)
2. [ ] Contact program officer to discuss fit
3. [ ] Refine specific aims based on feedback
4. [ ] Identify co-investigators (bioinformatics, LMIC partner)
5. [ ] Begin drafting Research Strategy
6. [ ] Prepare letters of support
7. [ ] Finalize budget with institutional support
</pre></div><button class="expand-btn">Show more</button></div>
</div></div></div>
<div class="message tool-reply" id="msg-2025-12-14T23-30-18-756Z"><div class="message-header"><span class="role-label">Tool reply</span><a href="#msg-2025-12-14T23-30-18-756Z" class="timestamp-link"><time datetime="2025-12-14T23:30:18.756Z" data-timestamp="2025-12-14T23:30:18.756Z">2025-12-14T23:30:18.756Z</time></a></div><div class="message-content"><div class="tool-result"><div class="truncatable"><div class="truncatable-content"><pre>File created successfully at: /Users/scotthandley/Code/novel-FGT-approaches/parent-R21-proposal.md</pre></div><button class="expand-btn">Show more</button></div></div></div></div>
<div class="message assistant" id="msg-2025-12-14T23-30-29-280Z"><div class="message-header"><span class="role-label">Assistant</span><a href="#msg-2025-12-14T23-30-29-280Z" class="timestamp-link"><time datetime="2025-12-14T23:30:29.280Z" data-timestamp="2025-12-14T23:30:29.280Z">2025-12-14T23:30:29.280Z</time></a></div><div class="message-content">
<div class="assistant-text"><p>Done. I've created a comprehensive R21 proposal document at <code>/Users/scotthandley/Code/novel-FGT-approaches/parent-R21-proposal.md</code>.</p>
<h2>Summary of the Document</h2>
<p>The proposal includes:</p>
<p><strong>Administrative details:</strong>
- Target: PA-25-304 (Parent R21)
- Budget: $275K over 2 years
- Recommended deadline: June 16, 2025
- Primary IC: NIAID (HIV/infectious disease angle)</p>
<p><strong>Three Specific Aims:</strong>
1. Develop and optimize the multi-amplicon panel (cpn60, rpoB, functional genes)
2. Create bioinformatics pipeline (UMI processing, concordance, functional scoring)
3. Validate platform and develop LMIC qPCR derivative</p>
<p><strong>Key sections:</strong>
- Significance and Innovation statements
- Preliminary data summary (your published and unpublished work)
- Detailed approach with primer design, multiplexing, and pipeline architecture
- Timeline (Year 1: development/optimization; Year 2: validation/publication)
- Budget justification
- Expected outcomes with specific metrics
- Future directions (path to R01)</p>
<p><strong>Next steps checklist</strong> at the end for tracking progress.</p>
<hr />
<p><strong>Questions to refine:</strong></p>
<ol>
<li>
<p><strong>Co-investigators?</strong> Would you want to include a bioinformatics co-I (Kris Sankaran or Laura Symul from the FRESH grant?) or keep this as single-PI?</p>
</li>
<li>
<p><strong>LMIC partner?</strong> Should the qPCR deployment aim include a named South African collaborator?</p>
</li>
<li>
<p><strong>Program officer contact?</strong> Want me to help identify the appropriate NIAID program officer to contact before submission?</p>
</li>
</ol></div></div></div>
        

<div class="pagination">
<a href="index.html" class="index-link">Index</a>
<a href="page-003.html">&larr; Prev</a>
<a href="page-001.html">1</a>
<a href="page-002.html">2</a>
<a href="page-003.html">3</a>
<span class="current">4</span>
<span class="disabled">Next &rarr;</span>
</div>

    </div>
    <script>
document.querySelectorAll('time[data-timestamp]').forEach(function(el) {
    const timestamp = el.getAttribute('data-timestamp');
    const date = new Date(timestamp);
    const now = new Date();
    const isToday = date.toDateString() === now.toDateString();
    const timeStr = date.toLocaleTimeString(undefined, { hour: '2-digit', minute: '2-digit' });
    if (isToday) { el.textContent = timeStr; }
    else { el.textContent = date.toLocaleDateString(undefined, { month: 'short', day: 'numeric' }) + ' ' + timeStr; }
});
document.querySelectorAll('pre.json').forEach(function(el) {
    let text = el.textContent;
    text = text.replace(/"([^"]+)":/g, '<span style="color: #ce93d8">"$1"</span>:');
    text = text.replace(/: "([^"]*)"/g, ': <span style="color: #81d4fa">"$1"</span>');
    text = text.replace(/: (\d+)/g, ': <span style="color: #ffcc80">$1</span>');
    text = text.replace(/: (true|false|null)/g, ': <span style="color: #f48fb1">$1</span>');
    el.innerHTML = text;
});
document.querySelectorAll('.truncatable').forEach(function(wrapper) {
    const content = wrapper.querySelector('.truncatable-content');
    const btn = wrapper.querySelector('.expand-btn');
    if (content.scrollHeight > 250) {
        wrapper.classList.add('truncated');
        btn.addEventListener('click', function() {
            if (wrapper.classList.contains('truncated')) { wrapper.classList.remove('truncated'); wrapper.classList.add('expanded'); btn.textContent = 'Show less'; }
            else { wrapper.classList.remove('expanded'); wrapper.classList.add('truncated'); btn.textContent = 'Show more'; }
        });
    }
});
</script>
</body>
</html>